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INTRODUCTION: 
 
           Retina is the most common part in the eye to get affected by various systemic 
disorders like diabetes,hypertension, anemia,  etc. There are also numerous organ 
specific problems like retinal breaks ,detachment,infections,inflammation, tumors etc. 
           Most of all the above problems can be effectively treated by lasers. Initially 
sunlight was thought to be curative.It was demonstrated by Meyer Schwikerath. Later, 
arc lamp lasers were used .However because of its larger size and its tendency to 
produce retinal burns it wsa abandoned. After that numerous lasers like ruby laser, Nd 
yag laser,aron laser, dye laser, krypton lasers were used . Now it is an era of portable 
lasers that is semiconductor diode laser. 
          In my study, doubled frequency Nd YAG laser is used. 
          It uses a wavelength of 532 nanometers. 
          Eye in its relaxed state, has an optical power of  60 D.  Corneal power being  
40D two thirds of the total power of the eye .Crystalline lens having 20D in a fully. 
relaxed state. In a fully accommodated state , it has a power of 33D. 
          Light entering the eye can be either reflected, scattered or transmitted or 
absorbed.Reflection or scattering of entering light can be used for noninvasive 
diagnostic purposes.Absorpton characteristics is dependent on the chromophore 
present in the eye. It is being used in lasers.  
  
 
      
2 
 
 
ANATOMY OF RETINA: 
          Optic vesicle gives rise to pigment epithelium of retina, sensory layers of retina, 
 epithelium of iris and ciliary body. The surface area is almost 266 mm
2
 being thickest 
near the optic disc and thinnest in the periphery. 
           Area centralis is the portion of the retina lying between the vascular arcades. It  
is 5.5 mm in diameter. It constitutes the central 15 degree of visual field.  
           Fovea is 1.85 mm in diameter. It constitutes the central 5 degree of visual field 
           Foveola is 0.35 mm in diameter . It constitutes the central 1 degree of visual 
field. It has the highest degree of cone photoreceptors and it is an avascular area.It has 
 the highest degree of visual acuity. 
           Parafovea is the area 0.5mm in diameter around the fovea. Perifovea is 1.5 mm 
 in diameter around the parafovea 
            Macula is the central region of the retina.It is about 3mm in diameter .It 
contains xanthophyll. 
The peripheral retina is again classified into near periphery, mid periphery and 
far periphery.The near periphery is the 1.5 mm zone around the area centralis.The mid 
periphery is a 3 mm wide zone.The far periphery is 9 to 10 mm wide from the 
temporal side of the optic disc and 16 mm from the nasal side of the optic disc. 
               Anteriormost part of the retina is ora serrata.The inner layer continues as non 
 pigmented layer of the pars ciliaris retinae. The outer RPE layer continues as the 
pigmented cuboidal layer of the ciliary body 
 
3 
 
               The outer retinal barrrier is formed by RPEcells.Hoistolologically saying 
terminal bars between RPE cells. 
The inner retinal barrier is formed between retinal capillary endothelial cells. 
The main action of Laser is in RPE and choriocapillaries. 
s 
LAYERS OF RETINA: 
 
Layers of retina from sclera to vitreous 
 1) Retinal pigment epithelium 
 2) Photoreceptors  
 3) External limiting memberane 
 4) Outer nuclear layer 
 5) Outer plexiform layer 
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 6) Inner nuclear layer 
 7) Inner plexiform layer  
 8) Ganglion cell layer 
 9) Nerve fibre layer 
10) Internal limiting memberane. 
 
LASERS: 
LASER stands for Light Amplification by Stimulated Emission of Radiation. 
Laser has three important properties. That is they are monochromatic, coherent and 
they have limited divergence.  
            Electrons exist around an atom at various energy levels. They can come down 
to a lower energy level or go up to a higher energy level. 
             They raise to higher energy level by absorbing a photon or fall to a lower 
energy level by releasing a photon. 
             Electrons in the medium of laser are excited to a higher energy state. 
             Then they come to a lower energy state by stimulated emission or 
spontaneous emission. Here the atom encounters a photon equal in energy to the 
difference between higher energy levels and lower energy levels. 
             When the rate of pumping atoms to the higher energy state is greater than the 
rate of decay to the lower energy state population inversion occurs. 
             Then the amplification is done by mirrors with emission of laser light.  
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LASER TISSUE EFFECTS: 
PHOTOCHEMICAL EFFECTS: 
       It occurs when ultraviolet or visible light causes formation or destruction of 
chemical bonds.It results in the formation of molecules that is toxic to the cell. 
       The excimer laser cuts tissues by breaking the organic bonds 
 
THERMAL EFFECTS 
        It is seen in retinal photocoagulation.Absorption of visible or infrared light 
causes increase in the temperature of 10 to 20 degree Celsius which photocoagulates 
or denatures the absorbing tissues. 
         Several pigments absorb laser energy.Xanthophyll  maximally absorbs blue 
wavelength. 
Hemoglobin anbsorbs blue , green ,yellow wavelength but maximally absorbs yellow 
wavelength. Melanin absorbs all wavelengths and is maximally located in retina 
pigment epithelium 
 
VAPORISATION: 
         It occurs with either visible or infrared light. It causes the temperature to rise 
above the boiling point and causes micro expulsion to occur within the cells. It occurs 
with carbon dioxide laser and in an intensely overt argon laser burn. 
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OPTICAL BREAKDOWN: 
         It occurs with the infrared light of the Nd YAG laser. It results in plasma 
formation with the electrons stripped from the atom or molecules resulting in a shock 
wave that disrupts the tissue. This is used in iridotomy and capsulotomy using Nd 
YAG laser. 
 
MECHANISMS OF PHOTOCOAGULATION IN RETINAL DISEASES: 
SCATTER PHOTOCOAGULATION FOR NEOVASCULARISATION: 
         The main pathology in retinal diseases planned for PRP is retinal hypoxia and 
increased vasoproliferative factors.PRP causes photocoagulation of RPE and causes 
increased retinal oxygenation decreasing the liberation of vasoproliferative factors. 
 
MACULAR EDEMA: 
       Grid photocoagulation is used. It causes endovascular thrombosis and 
vasoconstriction of the leaking microaneurysms. It causes increased oxygenation of 
the inner retinal layers  by photocoagulating RPE thereby  strengthening the inner 
BRB.It debrides the diseased  RPE causing new cell to proliferate strengthening the 
outer BRB. 
 
CHOROIDAL NEOVASCULARISATION : 
        Laser applied directly to the vessels causes endovascular thrombosis and 
vasoconstriction . Hypertrophy of RPE also occurs following laser and it may 
influence the outcome. 
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IDIOPATHIC CENTRAL SEROUS CHORIORETINOPATHY: 
        In this laser removes diseased RPE .The diseased area is replaced by new RPE 
cells which strengthens the RPE pump.This causes resolution of CSR. 
 
RETINAL VASCULAR ANOMALIES: 
         Retinal vascular tumors directly absorb laser energy.This causes heat induced 
contraction of the vascular wall .This also causes endovascular thrombosis 
 
NON VASCULAR INTRAOCULAR TUMORS: 
         Retinoblastoma are amelanotic.They poorly absorb laser energy. Heavy 
confluent retinal burns are given over the tumor . They close the overlying vascular 
supply and cause tumor necrosis. 
           Choroidal melanomas are pigmented tumors. They are melanotic. Heavy 
confluent  burns are given around the tumor which cut off the vascular supply. Burns 
over the tumor which are confluent causes tumor necrosis. 
 
RETINAL BREAKS: 
            Photocoagulation creates chorioretinal adhesion around the break.It causes 
adhesion between retinal pigment epithelium and neurosensory layers. Thus it seals 
the subretinal space from the vitreous cavity. The adhesion reaches its full strength 
several weeks following treatment. 
             It causes less breakdown of the blood retinal barrier thus lesser risk for 
proliferative vitreolretinopathy compared to cryotherapy. 
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            Laser photocoagulation in shallow RD surrounding retinal breaks  had resulted 
in resorption of subretinal fluid. Possible mechanisms being activation of RPE pump 
and fibrinous reaction between RPE and the sensory retina which may temporarily 
tamponade the break. 
 
TYPES OF LASER PHOTOCOAGULATORS: 
 
               
ARGON BLUE GREEN LASER (488 to 514 nanometers): 
         It is absorbed by xanthophyll, hemoglobin, melanin. As it is absorbed by 
xanthophyll it can damage the macula when used for grid photocoagulation. It causes 
high intraocular scattering. It is absorbed by hemoglobin so it can cause inner retinal 
damage when given in a case of vitreous haemorrhage. It is absorbed by melanin in 
RPE so it can be used for scatter photocoagulation if the above situations doesn’t 
coexist. 
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ARGON GREEN LASER(514nanometers): 
          It is absorbed br hemoglobin and melanin..It can be used for juxtafoveal 
photocoagulation since it is not absorbed by xanthophyll 
Frequency doubled Nd YAG laser(532nanometers )and dye yellow laser(560to 
580nm): 
         They both share common characteristics. They are absorbed by hemoglobin and 
melanin.They cause less intraocular scattering when compared to argon blue green 
laser.Since it is also absorbed by hemoglobin it can’t be used in vitreous haemorrhage. 
It can be used for photocoagulating  new vessels  and in pale fundi as it can directly 
act on choriocapillaries. 
 
KRYPTON RED LASER(647nm) and DYE RED LASER(610 to 640 mm): 
       It is absorbed only by melanin.It can be given through vitreous haemorrhage.It is 
more painful because of deeper penetration.It can be given for scatter 
photocoagulation.It is not of much use in pale fundi. 
 
SEMICONDUCTOR DIODE LASER(805 nm to 810 nm ): 
       It is relatively inexpensive , portable and air cooled instrument.It is absorbed by 
melanin only so the properties are similar to red lasers. 
 
PROCEDURE OF PHOTOCOAGULATION: 
INFORMED CONSENT: 
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      It is both legal and educational process to the patient.Consent must include the 
problem what the patient is having, what will happen if left untreated, what are the 
complications of the procedure with the patient signature. 
 
ANAESTHESIA: 
        More commonly topical anaesthesia is used. Retrobulbar block can be given in  
cases of significant ocular pain, significant eye movement and treatment adjacent to 
foveal centre. 
 
PHOTOCOAGULATION DELIVERY SYSTEMS: 
SLIT LAMP DELIVERY SYSTEM: 
 1)CONTACT LENSES: 
a)ALL PURPOSE FUNDUS CONTACT LENSES 
       Goldmann three mirror lenses:  3 mirrors at angles of 59 deg,67deg,73deg. They 
provide visualisation from the ora serrata to posterior pole. 
    Karickhoff lens: four mirrored lens  angled at 62 deg,67deg,76deg,80deg for  
viewing from the ora serrata to the arcade area. 
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CONTACT LENS FOR MACULAR PHOTOCOAGULATION : 
           They provide a real inverted image for the fundus. They provide a wider field  
of view and higher magnification. This includes Volk SuperMacula2.0, Volk Area 
 Centralis, Mainster high Magnification, Mainster Standard lenses.  
 
CONTACT LENSES FOR PERIPHERAL PHOTOCOAGULATION: 
               They provide wide angled, mini field, inverted fundus image. They include 
Rodenstock Panfundoscopic lens, VolkbTransequator, Volk quadraspheric, Mainster  
Ultra field, Volk Superquad 160 lenses. 
 
PEYMANN Nd YAG VITREOLYSIS CONTACT LENSES: 
          They are convex surfaced contact lenses with radii of 12.5, 18.0, 25.0mm  
curvatures that are used for anterior, mid, posterior vitrolysis respectively. 
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NON CONTACT LENSES: 
             Lenses that can be used are 60D, 78D,90D. They can be used in case of  
recurrent corneal erosions, postoperative corneal wound or following tarssorraphy. 
 
B)INDIRECT OPHTHALMOSCOPE DELIVERY SYSTEM: 
                 It is used for panretinal photocogulation.It is used in cases of retinopathy of 
prematurity, intermediate uveitis(pars planitis),Coats disease, retinal breaks,   
detachment,  retinoblastoma, choroidal malignant melanoma, retinal photocoagulation 
 following pneumatic retinopexy . 
 
APPLICATIONS OF PHOTOCOAGULATION 
1)Observerrs within 1 metre of the laser contact lens should wear the protective laser 
 goggles to decrease the risk of retinal damage.The treating physician is protected by 
 filters in the laser. 
2) LASER SETTINGS: 
SLIT LAMP SETTINGS: 
MAGNIFICATION: 
       Lower magnification for peripheral treatment. Higher magnification for macular 
 treatment  
WAVELENGTH SELECTION: 
        Longer wavelengths of krypton red, dye red, diode  lasers have less 
 intraocular scattering and are able to penetrate through vitreous haemorrhage and they 
 penetrate deeply. 
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SPOT SIZE:  
         Spot size is dependent on the region of the eye to be treated that is, macula  
versus periphery. Macular photocoagulation the size ranges from 50 to 200 microns. 
Scatter photocoagulation the size ranges from 200 to 1000 microns. Shorter 
wavelengths produce larger burn size. 
AIMING BEAM INTENSITY: 
          Aiming intensity must be as less as possible .There is a increased chance for 
decreased colour contrast sensitivity if aiming beam is high. 
 
BURN INTENSITY:  
Chorioretinal burn intensity can be classified into 
   Light: barely visible retinal blanching 
   Mild: faint white retinal burn 
   Moderate: opaque dirty white retinal burn. 
   Heavy: dense white retinal burn. 
Laser retinal burn opacification is due to protein desaturation in the outer retina.    
Laser energy is unable to penetrate deep to retinal whitening. Burning beyond this 
may lead to inner retinal damage.  
     Light intensity burns for macular grid photocoagulation. Moderate intensity burns 
for scatter photocoagulation. Heavier intensity burns when tissue destruction is 
desired Eg choroidal neovascularisation and tumors. 
     Greyish retinal discolouration is the end point for diode laser and chalky white 
burn is the end point for argon green laser. 
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      Burn intensity can be increased by increasing the burn duration and power output  
and decreasing the spot size .It is better to increase the burn duration than to increase  
the power output. 
       Burn intensity can be decreased by decreasing the burn duration and decreasing  
the power output and increasing the spot size. 
 
LASER INDIRECT OPHTHALMOSCOPE PHOTOCOAGULATION: 
         It is more painful when compared to slit lamp delivery systems.  
 Here the retinal spot size increased by increasing the power of condensing lens and  
by increasing the increasing the image plane spot size and is inversely proportional to  
power of the patient’s eye. 
         Decreased retinal spot size is seen in myopia and gas filled phakic eyes. 
         Increased spot size is seen in hypermetropia and gas filled aphakic eyes. 
         Post operatively mild analgesics are given. 
 
COMPLICATIONS OF LASER PHOTOCOAGULATION: 
ANTERIOR SEGMENT COMPLICATIONS: 
1)ELEVATED INTRAOCULAR PRESSURE: 
             It can be caused by angle closure due to choroidal effusion or due to transient  
decrease of outflow through open angles.The peak increase is seen 1 day after  
photocoagulation and it returns to normal within 1week. 
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2)CORNEAL DAMAGE: 
            There may be corneal erosion following laser. It is more common in patients  
with diabetes mellitus  and in patients with recurrent corneal erosions. Cornea should  
be examined for abrasion immediately after treatment and bandage contact lens  
should be applied if epithelial defect is there. 
            Corneal edema may be present soon after laser due to aqueous 
overheating.Subtle corneal endothelial loss also seen. Corneal sensitivity may also be 
damaged.This can be reduced by shorter duration, larger size, lower burns intensity.  
In ROP laser there may be focal temporary or permanent epithelial defects. This can  
be reduced by the lubricating the corneal surface ,denuding the  corneal epithelium  
thus reducing the Edema, and precisely focusing the aiming beam during laser 
photocoagulation. 
 
IRIS BURNS: 
            Iris burns with anterior uveitis, posterior synechiae, iris atrophic patches are  
noted.This can be avoided by precisely focusing and by doing laser in a well dilated  
pupil. 
CRYSTALLINE  LENS BURNS: 
              Focal gray white anterior cortical opacities which are non progressive may be  
present.It is usually due to smaller size, longer duration, high power burns.In ROP, it  
is due to pupillary miosis, absorption by the tunica Vasculosa lentis, choroidal  
lenticar apposition due to uveal effusion. Aiming beam not properly focused,  existing 
cataract or pigment on the lens surface can cause cataract. Cataractous   change is less 
commonly caused by yellow, red, diode lasers. 
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IOL AND POSTERIOR CAPSULE DAMAGE: 
          It can occur if there is pigment over the iol. Blue colour of the haptic may also  
be a cause. 
INTERNAL OPHTHALMOPLEGIA AND ACCOMODATIVE PARESIS: 
            It is due to damage of the parasympathetic nerves in the suprachoroidal space.  
There is also loss of accommodation. 
B)PAIN: 
               It is due to photocoagulation of the ciliary nerves in the suprachoroidal  
space. It is more while photocoagulating along horizontal meridians and anteriorly. It  
can be minimised with shorter duration and less intense burns. 
C)SEIZURE: 
                 It is a rare complication. It can be due to oculocardiac reflex  from pressure  
on the eye and due to photic stimulation. 
D)CHOROIDAL DETACHMENT AND EXUDAIVE RETINAL DETACHMENT: 
                Choroidal detachment is due to obstruction of choroidal veins and overtly  
choroidal inflammatory reaction. Retinal detachment is due to damaged choroidal  
vessels leaking fluid through RPE cells which are damaged by photocoagulation.  
Both are usually self limited. They may cause secondary angle closure glaucoma and  
choriolenticular apposition resulting in cataract. This may be avoided by avoiding  
longer red and diode wavelengths. 
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E)CHOROIDAL,SUBRETINAL AND VITREOUS HEMORRHAGE: 
                Vitreous hemorrhage is due to photocoagulating elevated new vessels. More  
commonly small and shorter duration burns. It can be treated by increasing the  
pressure over the globe and applying larger and longer duration burns over the  
bleeding area. 
 
F) THERMAL INDUCED RETINAL VASCULAR DAMAGE: 
               Retinal vasculitis is common with NdYAG, argon green and dye yellow  
wavelengths. It occurs following photocoagulating choroidal neovascularisation,  
retinal neovascularisation, retinal artery macroaneurysms. Both branch retinal artery  
occlusion and branch retinal vein occlusion may occur. It is usually self limited.This  
can be avoided by photocoagulating away from larger retinal vessels. 
 
G) PRERETINAL MEMBERANE: 
                  It is due to inner retinal damage. It can be minimised by avoiding intensive  
burns , photocoagulating over intraretinal haemorrhages, argon blue green  
photocoagulation.  
 
H)ISCHAEMIC PAPILLITIS: 
               It is a photocoagulation induced optic nerve damage by photocoagulating   
optic disc surface or disc margin. 
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I)PARACENTRAL VISUAL FIELD LOSS OR SCOTOMA: 
               It is common following macular grid photocoagulation and photocoagulation  
for choroidal neovascularisation and optic nerve damage. It can be decreased by  
avoiding overtly intense large burns for macular photocoagulation and by avoiding  
argon blue green laser. 
 
J)PHOTOCOAGULATION SCAR ENLARGEMENT AND SUBRETINAL 
FIBROSIS: 
             It is unavoidable following photocoagulation. It causes paracentral visual loss 
 for macular grid photocoagulation. In photocoagulation for ARMD and ocular  
histoplasmosis the scar does not reach the foveal center but in cases following myopic  
CNVM it may reach the foveal centre and also in grid lasers for diabetic macular  
edema . 
 
K)IATROGENIC CHOROIDAL NEOVASCULARISATION: 
             It occurs with smaller size, longer duration and high intense burns. It is  
common with longer wavelength lasers. 
L)ACCIDENTAL FOVEAL BURN:  
             This can be minimised by instructing the patients not to move their eyes or in  
a more uncooperative patient retrobulbar anaesthesia can be given.Careful watching  
of the fovea must be done during photocoagulation. 
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J)VISION LOSS: 
               Near vision impairment can occur secondary to internal ophthalmoplegia . It   
can also be permanent. Myopia can also occur from zonular relaxation and anterior   
displacement of lens due to choroidal detachment . It gets corrected within a week. 
Macular edema may increase following PRP increasing the vision loss. It can be  
corrected by photocoagulating the leaking vessels before PRP. Colour vision loss and  
contrast sensitivity loss, visual field loss, abnormal dark adaptation, decreased  
electroretinogram and decreased night vision also can occur 
 
K)COMPLICATIONS FOLLOWING PHOTOCOAGULATING  
INTRAOCULAR MALIGNANT TUMORS: 
                Intraretinal and subretinal hemorrhage can occur. Vitreous seeding and  
theoretical way for contiguous spread and distant metastasis can occur. Tumor  
recurrence, branch retinal artery occlusion, branch retinal vein occlusion,  
neovascularisation, epiretinal memberane formation can occur.  
 
RETINAL DISEASEES IN WHICH LASER USED: 
DIABETIC RETINOPATHY: 
NON PROLIFERATIVE DIABETIC RETINOPATHY: 
         It is a microangiopathy resulting from the chronic effects of the disease . It more 
 commonly affects retinal vessels. 
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NATURAL HISTORY OF  NPDR: 
MICROANEURYSMS: 
      These are the hypercellular sacular outpouchings from the capillary wall. They are  
the initial manifestation for diabetic retinopathy. They can also be present in vascular  
occlusion and radiation retinopathy. They are 25 to 100 microns in diameter. They are  
due to loss of pericytes and increase in intraluminal pressure. 
 
RETINAL VASCULAR HYPERPERMEABILITY: 
        They are due to loss of pericytes and endothelial cells. There is leakage from the  
vessel wall, microaneurysms. Leakage from the vessel wall may result in retinal  
thickening. There may be inadequate resorption of plasma lipoproteins resulting in  
hard exudates. 
 DIABETIC MACULAR EDEMA: 
         They may be due to ischaemia and leakage . Even for ischaemia there may be  
leakage from the surrounding microaneurysms. It is characterised by thickening of  
the retina. 
CAPILLARY NON PERFUSION: 
         Ghost vessel are seen among the capillaries. As their number increase there may  
be closure of the arterioles. Then comes the formation of numerous microaneurysms  
and shunts resulting in the formation of intraretinal micro vascular abnormalities and  
intraretinal haemorrhages. As the closed  capillaries progressively increase in  
number, there occurs featureless retina without much intraretinal hemorrhages and  
hard exudates. 
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VITREOUS INTERFACE CHANGES: 
           There occurs a more common occurrence of epiretinal memberane formation in  
old age individuals with diabeties than without diabetes. Increased occurrence of  
vitreous liquefaction. There occurs increased adherence of posterior cortical vitreous  
to retina which is found with vitrectomy. 
 
OTHER ASSOSCIATIONS 
DURATION OF DIABETES MELLITUS: 
      In patients less than 30years(type 1) incidence of diabetic retinopathy is 13% in  
the first 5 years duration , 90% in the 10 to 15 years duration. 
            In patients more than 30years who are on insulin incidence of diabetic  
etinopathy is 40% in the first 5 years and 84% in 10 to 15 years duration. 
       In patients more than 30 years who are on oral hypoglycaemic, the incidence of  
diabetic retinopathy is 23% in the first 10 years and 54% in the 10 to 15 years  
duration. 
HYPERGLYCEMIA: 
       Glycemic control is essential for the control of diabetic retinopathy. With  
intensive glycemic control there is a slight immediate progression in retinopathy  
which needs to be watched for severe npdr and pdr patients 
HYPERTENSION: 
      Keeping the blood pressure under control reduces the progression of retinopathy  
according to UKPDS and ACCORD study. 
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DYSLIPIDEMIA: 
       Its assosciated with increased hard exudates in diabetic retinopathy and its  
rogression. 
OTHER RISKS: 
      Anemia and diabetic nephropathy found to increase the severity of diabetic  
retinopathy.Pregnancy increase the severity of diabetic retinopathy. 
 
DRUGS: 
       Aspirin doesn’t have proven to reduce the risk of diabetic retinopathy but it  
significantly reduces the cardiovascular risk in diabetic patients.Sorbinil an aldose  
reductase inhibitor doesn’t found to have any effect in reducing the incidence or  
severity of diabetic retinopathy.Fenofibrate a peroxisome proliferator receptor alpha  
agonist and Ruboxistaurin a protein kinase C inhibitor have intriguing effect in  
reducing the severity of diabetic retinopathy but both these drugs are still under trial.  
 
CLASSIFICATION OF NON PROLIFERATIVE DIABETIC RETINOPATHY: 
MILD NPDR : Microaneurysms only 
MODERATE NPDR:More than just microaneurysms but less than severe NPDR 
SEVERE NPDR: One of the following 
      More than 20 intraretinal hemorrhages in all 4  quadrants 
     Venous beading in two or more quadrants 
     Intraretinal microvascular abnormalities in one or more quadrants 
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VERY SEVERE NPDR:Any two of the following 
        More than 20 intraretinal hemorrhages in all 4 quadrant. Venous beading in two  
or more quadrant.   Intraretinal microvascular abnormalities in one or more quadrants  
CLINICALLY SIGNIFICANT MACULAR THICKENING: 
1) Thickeningof the retina at or within 500 µm of the center of the macula 
2) hard exudates at or within 500 µm of the center of the macula, if associated 
with thickening of the adjacent retina (not residual hard exudates remaining 
after the disappearance of retinal thickening) 
      3) a zone or zones of retinal thickening one disc area or larger, any part of which is 
within one disc diameter of the centre of the macula. 
 
MANAGEMENT: 
1) Strict glycemic control 
2) Contol of other risk factors. 
3) FFA: To rule out any new vessels.To find whether the macular Edema is due  
to ischaemia or leakage. 
4) OCT:To quantify the central foveal thickness and mean volume in CSMT 
patients and to find the macular Edema in patients in which is not revealed 
fundoscopically. 
5) GRID/FOCAL:It is given for clinically significant macular thickening. Visual 
acuity range in ETDRS study is 20/32 to 20/320. In this direct treatment of all leaking 
microaneurysms 500 to 3000 microns from the centre of the macula and grid is given 
in the angiographic non perfusion area 500 to 3000 microns superiorly, inferiorly and 
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nasally from the centre of the macula, 500 to 3500microns temporally from the centre 
of the macula. No burns should be placed within 500 microns from the centre of 
thedisc. The wavelength used is green to yellow wavelength. The power used is 
50mw. The duration is 0.05 to 0.10seconds. 
The burn intensity is mild burn intensity (mild greyish).Above are according to 
ETDRS study. 
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6) ANTI VEGF: 
             Bevacizumab and ranibizumab are human murine monoclonal antibody 
binding  VEGF A, Pegaptanib an aptamer inhibiting VEGF A 165 isoform, Afliberept 
a fusional protein binding to VEGF A and Fc fragment of IgG1 molecule are used in 
diabetic retinopathy. 
 
7) CORTICOSTEROIDS:  
              They are of more use in pseudophakic patients.The corticosteroids used are 
flucinolone acetonide and triamcinolone and dexamethasone. 
 
PROLIFERATIVE DIABETIC RETINOPATHY: 
      It’s an advanced stage of diabetic eye disease in which new vessels grow on the 
retina or optic disc with proliferation into the vitreous increasing the chance of vision 
loss. 
 
Pathogenesis of diabetic retinopathy: 
              Hyperglycemia and metabolic demands results in alterations in the retinal 
vasculature which causes relative retinal ischaemia .This results in proliferation of 
numerous growth factors like fibroblast growth factor , vascular endothelial growth  
factor,platelet derived growth factor etc. Of significance, is the vascular endothelial 
growth factor which proved to be angiogenesis in vivo and invitro. 
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STAGES OF PROLIFERATIVE DIABETIC RETINOPATHY 
PROLIFERATION OF NEW VESSELS: 
         New vessels most commonly arise from veins. More common is the  
superotemporal quadrant next is the inferonasal quadrant. First the new vessels may 
occur anywhere on the retina. Next over the disc next over the iris and finally  
neovascular glaucoma. New vessels can be identified by its superficial location wheel 
like network, crossing the artery and vein.As the new vessels regress the central 
portion begins to clear.the periphery of the wheel will still be proliferating. 
New vessels are accompanied by fibrous and glial proliferation. 
High risk characteristics are new vessels over the disc one fourth to one third disc 
area,any amount of new vessels over the disc with vitreous hemorrhage, new vessels 
elsewhere of one half of the disc and with vitreous hemorrhage 
 
CONTRACTION OF THE FIBROVASCULAR PROLIFERATION: 
         As the fibrous extraretinal proliferation contraction occurs vitreous detachment  
occurs. This can be seen slightly as a slight elevation at the borders with Swiss cheese 
pattern in the neighbouring retina.At this stage recurrent vitreous hemorrhage, 
subhyaloid hemorrhage,hole ,protrusion of vitreous through the hole into the retina. 
 
DISTORTION OF THE RETINA WITH MACULAR DETACHMENT: 
         As the new vessels further contract there is tractional detachment of  
neurosensory retina with even pigment epithelial layer.Macular detachment accounts  
for the more severe visual loss. 
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RISK FACTORS ASSOSCIATED WITH PDR: 
DURATION OF DIABETES MELLITUS: 
      In type1 diabetes mellitus , no retinopathy with in 10 yrs duration but at 20 yrs  
50% has pdr. In type11DM on insulin 2% in NPDR before 10 years ,20% in pdr at 20  
years. In type 11 DM in non insulin group 5% before 10 years and 5% after that. If 
severe NPDR without glycemic control for 15 months they develop pdr. Intensive 
glycemic control leads to early worsening of retinopathy so careful monitoring needed 
for the first 3 to 12 months. 
 
OTHER RISK FACTORS: 
         Hypertension ,hyperlipidemia,,decreased plasma albumin, decreased hemtocrit, 
diabetic Nephropathy are the other risk factors. 
 
MANAGEMENT: 
1) Strict diabetic control 
2) Control of other risk factors 
3) Scatter photocoagulation:In older  patients  with  type  2  diabetes  who  
havevery severe  NPDR  or  early  PDR,  ETDRS  results  and  clinical 
impression  suggest  that  prompt  photocoagulation  is  probably  safer than 
deferral.  In  younger  patients  with  type  1  diabetes,  ETDRS results suggest  
that  there  is  little  to  lose  from  deferring  scatter photocoagulation  until  
high-risk  PDR  develops  assuming  appropriate compliance  with  follow-up.  
However,  even  in  younger patients,  when early  NVD   is accompanied  by  
28 
 
the  intraretinal  signs  of  severe  or  very severe NPDR   prompt  treatment  is  
generally  recommended.  On  the other  hand,  when  younger  patients  have  
only mild  intraretinal  lesions and  NVE   that  appear  stable,  an initial  
period  of  observation  is generally  recommended.  If  new vessels  are  
demonstrated  to  be  growing, photocoagulation  is usually  recommended.  
However,  these  eyes  often remain asymptomatic  for  many  years,  with  
little  new  vessel  growth  and often  demonstrate  spontaneous  regression  of  
the  new  vessels.  In such eyes  vitreoretinal  adhesions  tend  to  be  delicate,  
and  when posterior vitreous  detachment  occurs,  there  is  less  tendency  for 
traction  retinal detachment.  When the process of posterior  vitreous  
detachment  has reached  completion  in  such  an  eye,  new vessels  are  
likely  to  be  few, narrow,  elevated,  and  partially replaced  by  fibrous  
proliferations,  and there  may  be  little  to  be gained  from  photocoagulation  
at  this  stage unless  vitreous  hemorrhages  are  occurring.  Presumably  the  
reduced aggressiveness of  new  vessels  in  the  setting  of  posterior  vitreous 
detachment results  from  the  lack  of  the  posterior  vitreous  face  scaffold 
for proliferation  and  less  possibility  for  retinal  traction.  Other comorbid 
conditions must be taken into account before planning for deferral of 
photocoagulation.  
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Laser settings for scatter photocoagulation are wavelength used is argon green, Nd 
YAG green,dye yellow,red or diode. Duration is 0.1 to 0.5 seconds. Spot size is 500 
microns and it is a moderate intensity burn. 
There are high chances for developing macular edema following PRP.  This 
can be reduced by giving PRP in 2 or 3 sittings. 
 
RETINAL BREAKS: 
It is defined as a full thickness retinal defect. It can be classified based on its  
attachment to the vitreous base as 
 Oral(retinal dialysis): breaks occurring within the ora 
 Intrabasal: breaks occurring within the vitreous base  
 Juxtabasal: breaks occurring along the posterior border of the vitreous 
base 
 Extrabasal: breaks occurring behind the vitreous base 
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It can also be classified into retinal hole and retinal tear and also into symptomatic and  
asymptomatic retinal breaks. 
Risk factors for retinal breaks progressing into rhegmatogenous retinal detachment are 
positive family history, prior history of cataract surgery or aphakia, posterior 
capsulotomy, symptomatic, high myopia, assosciated horse shoe tear, assosciated  
localised retinal detachment. Posterior vitreous detachment if assosciated with  
vitreous hemorrhage and pseudophakic eyes have high chances of having the break  
and developing the retinal break in the future so they need to be closely monitored. 
Lattice degeneration may have assosciated holes. According to several studies  
this need not be treated unless the patient had RD in the fellow eye and symptomatic. 
          Treatment for retinal breaks either photocoagulation or cryotherapy. 
Photocoagulation is preferred as it cause less disruption of  blood retinal barrier. 
Cryotherapy is indicated in case of pre equatorial breaks or breaks assosciated  with 
opaque media. 
           Laser settings for retinal break photocoagulation . Wavelength used is argon  
Green and Nd YAG green, duration is 0.1 to 0.2 seconds ,retinal spot size is 200  to 
500microns and the intensity  is moderate retinal whitening. 
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BRANCH RETINAL VEIN OCCLUSION: 
             In BRVO , patients present with sudden decrease in vision, floaters in long  
standing cases due to vitreous haemorrhage.Some patients have no complaints if it is  
a nasal branch vein occlusion.In fundus in fresh BRVO wedge shaped superficial  
haemorrhages with venous dilatation and tortuosity seen.In old BRVO sclerosed  
vessel ,venous dilatation and tortuosity,few hemorrhages and collaterals are seen.If  
the occlusion is at the optic nerve head ,two quadrants are involved.If it is periphery  
to the disc,one quadrant is involved.  
More commonly involve the superotemporal quadrant. It is more common  in 
males and patients with systemic diseases like hypertension and diabetes mellitus.  
even in cases of diabetic retinopathy if the hemorrhages are concentrated in one  
quadrant that is asymmetric presentation between quadrants one must think of 
vascular occlusion. In case of young males inflammatory etiology must be ruled out. 
Bilateral involvement may also be a feature of systemic assosciation.  
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Figure shows wedge shaped hemorrhages along the superotemporal quadrant with  
Dilated and tortuous retinal veins. 
               In FFA,CNP areas ,neovascularisation,macular leakage or ischaemia has to 
be looked for.More than 10 disc diopters of CNP areas is considered ischaemic BRVO 
.In OCT,intraretinal cystoid edema ,hemorrhages ,backscattering seen.In  some old 
BRVO,tractional CME can be seen.Accoding to BVOS study, if there is  macular 
leakage and vision is less than 20/32 ,grid laser can be given.According to  BVOS 
study, once neovascularisation develops pan retinal photocoagulation can be  
given.There is no role for prophylactic PRP as the occurrence of vitreous  
haemorrhage is the same following photocoagulation before or after the appearance  
of new vessels  . SCORE study analysed the effect of grid photocoagulation with 1mg  
and 4mg triamcinolone found grid photocoagulation not much more effective than the  
rest.In BRAVOS study,grid laser was recommended if there is less than 50 microns   
decrease in CFT and less than 5 ETDRS letter gain after 3 monthly intravitreal  
injections.After improvement after the first three injections ,if there is less than  
50microns decrease inthickness in CFT and less than 5ETDRS letters gain,patient can  
be switched over to grid laser.Grid laser can be given till the periphery of the  
capillary free zone.Then FFA can be repeated after 2 months if there is any further  
leakage futher burns with the previous burns as landmark can be safely given.   
 
CENTRAL RETINAL VEIN OCCLUSION :    
It is more common in males in the age group of 65 years. The fellow eye  has a 
chance of getting the vascular  occlusion in 1% of cases.  
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Patient complain of sudden loss of vision .There may be an incidental   finding 
if the other eye is normal. Visual acuity ranges from 20/32 to perception of  light. 
Initial good visual acuity is assosciated  with good prognosis and poor visual  acuity is 
assosciated with poor prognosis. 
In fundus multiple superficial flame shaped hemorrhages and blot  
hemorrhages with varying amount of optic disc swelling, macular edema and  new 
vessels are present. 
Based on the perfusion status CRVO is classified into perfused, non  perfused 
and indeterminate. Perfused CRVO has less than 10 disc diopters of capillary  non 
perfusion areas. Non perfused CRVO has more than 10 disc diopters of capillary 
nonperfusion areas. Indeterminate is said in CRVO if there is lot of hemorrhages  
blocking the underlying perfusion. 
Perfusion status and visual acuity play important role in NVI and NVA. FFA 
shows delayed filling of central retinal vein. After some time depending on  the 
ischaemic status patient may develop new vessels over the retina and the disc  which 
is evident by the leakage. In macula, leakage or ischaemia may present. In OCT 
macular edema may be present. 
The most common risk factors are hypertension and diabetes mellitus. The  
others are hypercoagulable states,inflammatory pathology etc. 
Management involves control of the systemic risk factors. GRID doesnot cause 
any improvement  when compared to the untreated group according to CVOS report. 
            PRP is given in case of CRVO once neovascularisation develops. Prophylactic 
PRP is given in cases when there is extensive non perfused CRVO with other risk  
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factors like male gender, short duration, extensive hemorrhages and in patients in 
whom frequent ophthalmological examination is not possible. 
          Intravitreal corticosteroids like triamcinolone acetonide, fluinolone causes 
significant decrease in macular edema but it is also assosciated with increased  
chances of cataract and elevated IOP when compared to untreated eyes. Ozurdex is an 
intravitreal implant which is assosciated with less chances of cataract and  elevated 
IOP. 
           Intravitreal anti VEGF like ranibizumab and pegaptanib are approved for use in  
CRVO. 
           Other treatment are vitrectomy, chorioretinal anastomosis by NDyag laser,  
radial Optic neurotomy. 
 
OCULAR ISCHAEMIC SYNDROME: 
             It’s  also known as ocular angina or venous stasis retinopathy.Its due to partial 
 or complete carotid artery obstruction.In general, a 90% or greater stenosis of the  
ipsilateral carotid arterial system is present in eyes with the ocular ischemic  
syndrome.It has been shown that a 90% carotid stenosis reduces the ipsilateral central 
 retinal artery perfusion pressure by about 50%. The obstruction can occur within the  
common carotid or internal carotid artery. In about 50% of cases, the affected vessel  
is 100% occluded, while in 10% there is bilateral 100% carotid artery  
obstruction.Most common in age more than 65 years. 
More common in males.Many of  them present with  progressive loss of vision over 
weeks .12 % present with sudden loss of vision.Prolonged light recovery may be there 
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due to macular ischaemia.Scintillating scotama similar to migraine aura and amaurosis 
fugax may present.Pain may present due to NVG or ischaemia of the globe or 
dura.Vision may range from 20/20 to counting fingers or worse vision.At one year 
follow up 24% have 20/20 to 20/50 58% have counting fingers or worse 
vision.External collaterals are seen in the forehead. 
       In anterior segment examination, keratic precipitates may be seen in 
cornea.NVI is present in 50% of cases.IOP is not raised in cases of OIS even if the 
angle is closed by fibrovascular tissue because of the decreased perfusion of ciliary 
body.flare may be present but it does not exceed 2+.In posterior segment examination 
venous dilatation and beading present but tortuosity is not present.Dot and blot 
haemorrhages are seen in the midperiphery.cotton wool spots are seen. Cherry red 
spot may be seen in 12% of cases as the  when intraocular pressure exceeds the 
perfusion pressure.Microaneurysms may be seen in the posterior pole.NVD or NVE 
may be present.On pressure over the globe arterial pulsations may be seen. 
         
Figure showsNarrow beaded retinal arteries and dilated beaded but non tortuous 
retinal veins 
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         In FFA,delayed arteriovenous crossing time is noted,delayed choroidal filling is 
more specific,retinal arterial staining,macular leakage and  microaneuysmal leakage  
will be present.Optic Disc hyperfluorescence may be present.Retinal capillary non 
perfusion will also be noted. 
            In OCT,cystoid macular Edema.In electroretinography, both a and b waves are 
affected.Carotid angiography typically discloses a 90% or greater obstruction of the 
ipsilateral internal or common carotid artery in persons with the ocular ischaemic 
syndrome. Given that noninvasive tests, such as duplex ultrasonography and  
oculoplethysmography, have an accuracy of approximately between 88 and 95% 
detecting carotid stenosis of 75% or greater.  Carotid angiography is often indicated 
for potential surgical cases or cases in which there is doubt about the diagnosis.Visual 
evoked potentials or opthalmodynamometry is also useful for the diagnosis. 
         Since atherosclerosis is the most common cause anti platelet agents like aspirin 
and anti lipidemic drugs can be used.For carotid artery obstruction  carotid end 
arterectomy or superficial temporal artery and middle cerebral artery anastomoses can 
be done.For NVG PRP followed by filtering surgery gives better results.For posterior 
segment neovascularisation PRP can be done. 
 
RETINOPATHY OF PREMATURITY(ROP): 
             It’s a condition occurring in neonates with immature retina.Normally  inutero 
retinal vessels spurt from the optic nerve head at 4 months of gestation.They reach the 
nasal ora serrata  at 8 months of gestation temporally to the ora by term.Normally 
80%of the neonates has the mature retinal vasculature by term.The main cause for 
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ROP is exposure to increased oxygen saturation in the immediate newborn period 
accompanied by low birth weight,septicaemia,asphyxia, cyanosis,  apnea, mechanical 
ventilation,  intraventricular  hemorrhages,  seizures,  transfusions, septicemia,  in  
utero  hypoxia,  anemia,  patent  ductus  arteriosus,  and  vitamin  E deficiency.In ROP 
two types of cells play a role vanguard(spindle shaped cells that are precursor for 
endothelial cells) reguard( endothelial cells that form new vessels).Once exposed to 
increased oxygen saturation there occurs a vasoobliterative phase .With still more 
prolonged exposure there occurs vaso occlusive phase. This is followed by 
arteriovenous shunts. This is followed by increased production of VEGF which results 
in sprouting of endothelial cells .Almost 90% grow into the avascular 
retina.Remaining 10% pierce the internal limiting memberane and grow into the 
vitreous.These are the vessels that cause theROP.There are three zones in ROP.  
Zone1:with the optic disc as the centre and twice the disc to macula distance as  the 
radius. 
Zone 11: a circle drawn tangential to the nasal ora serrata temporally it reaches  till the 
equator. 
Zone 111: peripheral retina that is present temporal to zone 11 
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There are five stages in ROP 
         Stage 1: demarcation line between vascular and avascular retina 
         Stage 2: demarcation ridge between vascular and avascular retina 
         Stage 3: demarcation ridge with extraretinal proliferation  
         Stage 4: partial retinal detachment 
                  4a:extrafoveal retinal detachment 
                  4b:partial retinal detachment including the fovea 
         Stage 5: Total retinal detachment 
         Plus disease is characterised by iris neovascularisation,pupillary rigidity,vitreous 
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 haze, arterial tortuosity and venous dilatation.Threshold disease is characterised by 5  
contiguous or8 non contiguous clock hours of zone 1 or 11 ROP. Prethreshold ROP is 
 defined as any ROP in zone 1 or zone 11 ROP  stage 2 or 3 with or without plus  
disease.Zone 1 ROP is more complicated because stage 3 ROP itself can be  
associated with retinaldetachnent and ROP is due to vasculogenesis in this zone so it  
does not respond to Anti VEGF.Aggressive posterior ROP is more aggressive plus  
disease in the posterior pole compared to periphery. 
           The criteria for screening ROP according to AAO is gestatiaonal age less than  
30weeks and birth weight less than 1500 g .In Indian scenario gestational age  less  
than 34 weeks and birth weight less than 2000g.Screening must be done with the post  
conceptional age of 31weeks or 4weeks after birth whichever is later according to  
CRYO ROP and LIGHT ROP study.Screening can be done by indirect  
ophthalmoscopic examination or Ret cam.At today’s point of time the treatment   
options  for stage 1 to 3 are laser or Anti VEGF. Stages 4 and5 require surgical  
management 
According to ET ROP study indications for treatment are  
Administer peripheral ablation Observation 
Type 1 ROP  
Zone 11 
  Stage 2 or 3 with plus disease 
Zone 1  
   Stage 1,2 or 3with plus disease 
   Stage 3 without plus disease 
 
Zone 11 
   Stage 3 without plus 
disease 
Zone 1 
    Stage 1 or 2 without 
plus disease 
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For follow up according to ETROP study 
   1 week or less follow up 
 Zone 11 stage 3 without plus disease 
 Zone 1 stage 1 or 2 without plus disease 
   1-2 weeks follow up 
 Zone 11 stage 2 without plus disease 
 Zone 1 immature,no ROP 
 Zone 1 regressing ROP 
   2 weeks follow up: 
 Zone 11 stage 1 without plus disease 
 Zone 11regressing ROP 
   2-3 weeks follow up: 
 Zone 111 stage 1 or 2 without plus disease 
 Zone 11 immature no ROP 
 Zone 111 regressing ROP 
Rgressed ROP complications myopia,astigmatism ,strabismus , amblyopia , retinal 
detachment,angle closure glaucoma. 
 
CENTRAL SEROUS CHORIORETINOPATHY: 
         It’s a serous detachment of neurosensory retina.It occurs more common in males 
 with male :female ratio of 6:1.Most common age group is 30 to 50 years.Main  
pathology is hyper dynamic choroidal circulation with hyperpermeability of  
choriocapillaries.The most common association is increased endogenous or  
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exogenous corticosteroids.It’s common in Type A personality.Abnormal coagulation  
and platelet aggregation and helicobacter pylori infection  are found to have  
association with CSR.  
             Presenting symptoms are central scotoma ,metamorphosis,micropsia, 
macropsia, dyschromatopsia andblurred vision.Patient has improved vision with 
hyperopic correction. 
Fundus examination shows serous detachment at macula may be associated 
with PED.Few subretinal yellow deposits are also seen. 
 
FFA shows ink blot appearance or smoke stag appearance.ICG shows dilated 
choroidal vessels with late leakage with hypertrophic patches below the leaks.OCT 
shows serous detachment and PED. 
         CSR is mostly self limiting and the patient regains the initial vision. But in 
chronic cases there may be loss of vision due to RPE atrophy,photoreceptor segment 
disruption,secondary  CNV, subretinal lipid depositions.  
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          Differential diagnosis includes optic disc pit,VKH,ARMD,PCV.The main mode  
of management is generally observation.But if the CSR is more than 4 months there  
is increased chance for photoreceptors to get affected.Thus CSR more than 3months  
can be managed with photodynamic therapy with verteporfin .Its a preferred method  
for multifocal CSR. 
         If it’s a solitary well defined leak,focal laser with argon laser photocoagulation  
can be done. Though there is initial improvement there is increased chances for  
recurrence. 
         Anti VEGF also helps.Accidental treatment with rifampin for a patient resolved  
CSR.Anti H pylori treatment can also be given. 
 
EALES DISEASE: 
         It’s an recurrent occlusive vasculitis affecting peripheral retina.Its common in  
young men .Common age group involved is 20 to 40 years.More commonly  bilateral. 
Its more common in India. 
          Here occurs a vicious cycle of inflammation and occlusion leading to  
neovascularisation followed by its consequences.Initially inflammation sets in vessel  
wall leading to perivasculitis.This is followed by occlusion of the vessel with 
 increased metabolic demand due to inflammation leading to hypoxia.This is followed  
by neovascularisation and release of more inflammatory mediators and the vicious  
cycle sets in.Hypersensitivity to tubercular protein is found in many cases of EALES  
disease 
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Figure shows peripherally sheathed vessels with vitreous hemorrhage  and 
Epiretinal memberane in the posterior pole. 
 
There are four stages of  EALES disease as   
             Stage 1: mild peripheral perivasculitis 
             Stage 2: extensive inflammation involving larger vessels 
             Stage 3:neovascularisation and vitreous haemorrhage 
             Stage 4: tractional complications 
 
           Presenting symptoms are usually floaters.On fundus examination peripheral  
sheathing of  vessels , few sclerosed vessels may be seen in the same eye and in the  
other eye.vitreous haemorrhage may be present.Tractional bands and detachment can  
also be there. 
 
         FFA shows extensive CNP areas in the peripheral retina and neovascularisation   
mostly in peripheral retina. 
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          Diagnosis is by excluding the other causes of vasculitis like intermediate  
uveitis,TB,syphilis,sarcoidosis ,diabetic retinopathy,TORCH infections, Coats   
disease,FEVR,Idiopathic retinal vasculitis.  
        Treatment in the active stage is systemic steroids or steroids through  intravitreal 
or subtenons route.PRP should not be given in the active stage as it  promotes further 
inflammation and neovascularisation. Once the inflammation  becomes quiescent and 
only if there is neovascularisation PRP is advised.  
 
COATS DISEASE: 
 
        It’s a disease characterised by anomalous and telengiectactic vessels with  
intraretinal and subretinal haemorrhages with massive subretinal exudation. It’s  
common in men.It’s seen between 5 years and 63 years. 
         Coats believed that multiple anomalous vessels which may cause haemorrhage  
which in turn leads to  subretinal exudation.He thought toxoplasmosis may be  
cause.But the absence of response to anti inflammatory or anti infective contradicted  
the theory. Few believed that coats disease shared a common etiology of incomplete  
retinal vasculature with FEVR,FSHD and Norries disease.All shared a common  
mutation in WNF gene responsible for angiogenesis.Recently CRB1 gene mutation  
has been found.  
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Figure shows Young girl with stage 4 Coats disease. Total retinal detachment seen at 
Posterior surface of the lens. 
 
 There are 5 stages in Coats disease 
         Stage 1: Telengiectasia 
         Stage 2: Telengiectasia+Exudation 
                     A)extrafoveal 
                     B) foveal 
         Stage 3: Telengiectasia+Exudation +Retinal detachment 
A) Subtotal 
1)extrafoveal 
2) foveal 
B) Total retinal detachment 
       Stage 4: Telengiectasia+Exudation +Retinal detachment +glaucoma 
         Stage 5: phthisis bulbi 
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Most common presenting symptom painless vision loss43%,strabismus 23%, 
leukocoria/xanthocoria    pain  (3%),  heterochromia  (1%),  nystagmus  (1%),  and no 
symtoms(8%).On anterior examination, corneal Edema, iris 
neovascularisation,shallow anterior chamber,cataract. Fundus examination shows 
anomalous telengiectactic vessels,Exudation and retinal detachment.FFA shows 
anomalous retinal vessels which are leaky,vessel beading,CNP areas.  
Treatment for stage 1 is observation.stages with Exudation ,scatter 
photocoagulation or cryotherapy can be done.Scatter ablation done only in the leaky 
vessels and CNP areas.Extensive ablation may result in increased 
inflammation,choroidal detachment,progressive Exudation,sympathetic ophthalmia 
rhegmatogenous RD,creation of retina choroidal anastomoses.Surgical repair can be 
done for the eyes with advanced retinal detachment abutting the lens and eyes with 
associated rhegmatagenous RD.Anti inflammatory and Anti VEGF agents are under 
trial. 
RETINOBLASTOMA: 
          It’s a malignant tumour of childhood. It’s commonly seen in the age group of 5  
months to 3 years. It’s due to germ line mutation in the RB1 gene. The most  common 
presenting symptoms  are  leucocoria and strabismus. Strabismus below six  months 
should be looked for retinoblastoma. It may also present as angle closure  glaucoma or 
aseptic orbital cellulitis. 
          Retinoblastoma can be unilateral or bilateral, heritable or non heritable. Cells of  
origin for this tumor is retinoblasts. Vitreous and subretinal seeding due to PTEN  
tumor suppressor gene mutation.There may be also vitreous  
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haemorrhage,neovascularisation glaucoma. Optic nerve invasion ,extra ocular  
extension and extra orbital extension can occur. Ultimately it may involute by itself  
causing phthysis bulbi. 
            Previous classification of retinoblastoma is Reese – Ellsworth classification.  
It’s obsolete now. Now the classification followed is International Classification of  
Intraocular Retinoblastoma based on systemic chemotherapy response  
Group A: ( Very low risk ) 
Small discrete intraretinal tumor away from the disc and foveal  
Group B:( low risk) 
All other discrete intraretinal tumor s without vitreous seeding 
Group C: ( moderate risk ) 
Discrete local disease with minimal vitreous or subretinal seeding 
Group D: ( high risk ) 
Diffuse disease with focal and/or vitreous or subretinal seeding 
Group E: (very high risk ) 
Presence of any one or more of these prognostic features 
Neovascular glaucoma 
Tumor touching the lens 
Tumor extending anterior to the anterior hyaloid phase involving the ciliary body  
Diffuse infiltrating retinoblastoma 
Dense vitreous haemorrhage 
Necrosis causing aseptic orbital cellulitis 
Phthysis bulbi 
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Once the child is clinically suspected of having retinoblastoma, can proceed 
with  Bscan.B scan shows intraocular calcification. CT orbit can also be done if B 
scan  doesn’t show intraocular calcification but the child is exposed to some radiation.  
MRI orbit can be done to rule out optic nerve invasion and extraocular extension.  
MRI brain to rule out trilateral retinoblastoma. If metastasis is suspected CSF  
analysis and bone scan to the patient.Staging examination under anaesthesia should  
be done. 
       The treatment should be like approach to the child as a whole but not to the eye  
Alone. 
 
UNILATERAL RETINOBLASTOMA: 
Group A: Laser or cryotherapy 
Group B: two to three cycles of chemotherapy with two or three drug regimen  
ollowed by focal consolidation 
Group C:6 cycles systemic chemotherapy with carboplatin ,etoposide, vincristine 
Group D and E: enucleation 
 
BILATERAL RETINOBLASTOMA:symmetrical 
Group A: laser or cryotherapy 
Group B:brachytherapy 
Group C:unilateral group C protocol must be followed even if fovea of one eye is 
destroyed by  the tumor 
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Group D: 6 cycles of three drug chemotherapy with three cycles of local subtenon  
Carboplatin or 6 cycles of three drug chemotherapy with external beam radiation. 
 
In advanced intraocular disease of one eye in bilateral disease chemotherapy may be 
 considered before enucleation. 
 
Figure shows focal laser consolidation of retinoblastoma. First laser  spots are placed  
in the margins half on the tumor and half off the tumor. Then they are overlapped by  
Spots placed over the tumor overlapping 30% of the previous spot. 
 
CHOROIDAL MELANOMA: 
       It’s most common in old age males. Higher the age higher is the incidence. It can 
 also occur in females. White race is more commonly affected. There is no proven  
relation between choroidal nevi and melanoma however dysplastic nevus syndrome  
or atrophic mole has some relations. There is no proven relation between sunlight  
exposure and uveal melanoma however high amount of UV radiation can cause this.   
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G alpha mutation is seen. 
There are many ocular salvageable therapies for melanocytoma nowadays. 
They are radiation and non radiation therapy and surgical therapy. Radiation therapy  
are iodine 125 plaque therapy ,ruthenium 106 therapy and protonbeam irradiation. 
Iodine therapy is found to have the least recurrence. Non radiation therapy are laser 
photocoagulation ,photodynamic therapy and transpupillary therapy. Surgical ocular 
alvageable therapy is transscleral endoresection and vitrectomy with resection. 
Larger tumor, anterior location,superficial location, rapid regression after 
plaque therapy,histologically epitheliod type and high relative tumor vascular density 
are associated with increased risk of metastasis. The most common site of metastasis 
is liver followed by lung. 
Small  asymptomatic  melanocytic  tumors  of  the  posterior  uvea  that  exhibit 
dormant  features  can  probably  be  observed  periodically  without any  treatment 
until  definite  evidence  of  growth  is  documented. Some  small  choroidal  
melanomas  that  were  previously  treated with  photocoagulation  are  now  being 
treated  with  newer  techniques  of  transpupillary  thermotherapy. Radiotherapy  can 
be  employed  using  episcleral  plaques  or charged  particle  treatment.  Selected 
melanomas  of  the  ciliary body  and  peripheral  choroid  can  be  treated  by  local 
resection techniques.  Local  resection  has  theoretical  advantages,  but  the surgery 
takes  longer  and  the  immediate  complications  are potentially  greater. 
Enucleation  is  generally  indicated  for  most  large  melanomas greater  than 
15  mm  in  diameter  and  greater  than  10  mm  in  thickness.  It  is  also  generally 
indicated  for  tumors  that  have  invaded the  optic  nerve.  It  does  not  appear  that 
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pre-enucleation  radiotherapy  improves  patient  survival. Orbital  exenteration  is  
ustified  for  advanced  uveal  melanomas  with  massive  extraocular  extension.  Its 
value  in  the  management  of  smaller  degrees  of  extraocular  extension  is 
uncertain. Such  patients  can  often  be  managed  by  methods  of  radiotherapy. It 
currently  appears  that  chemotherapy  and  immunotherapy  do not  provide  a 
therapeutic  cure  for  uveal  melanomas  but  their true  effectiveness  awaits  the 
results  of  further  studies. 
Photocoagulation  treatment  is  started  by  circumvallating  the tumor  with  
an  intensive  chorioretinal  scar  followed  by  direct treatment  of  the  tumor  with   
high-ntensity  burns  including  disruption  of  the  tumor  tissue  and  occasionally   
appearance  of  gas bubbles  inside  the  target  tissue.  As  expected,  this  technique  
may result  in  numerous  treatment-related  retinal  complications including  retinal 
breaks,  epiretinal  membrane  formation  vascular  occlusion  and  tractional  retinal  
detachment.  Moreover,  only small  tumors  can  be  treated  and  even  in  this  subset  
of  small tumors  a  relatively  high  recurrence  rate  of  uveal  melanomas after  
photocoagulation  treatment  has  been  reported.  In  particular,  extrascleral   
extension  of  the  melanoma  may  occur  growing underneath  the  fibrous  scar   
overlying  the  tumor  remnants.  Consequently,  photocoagulation  treatment  as  sole  
treatment  of a  uveal  melanoma  has  been  abandoned  in  most  centers. 
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MISCELLANEOUS DISODERS WHERE LASERS USED: 
OPTIC NERVE HEAD PIT: 
            Here confluent burns are placed on the temporal aspect of the disc margin so 
that  pit gets sealed off from the subretinal space. 
 
RETINAL ANGIOMA: 
            It is more common in cases of Von Hippel Lindau syndrome in which feeder 
vessel to the tumor is photocoagulated. Thid prevents further complications of the 
tumor like neovascular glaucoma and exudative RD. 
 
DIFFUSE UNILATERAL SUBACUTE NEURORETINITIS: 
           It is cause by subretinal nematode like Baylisascaris procynis . it can remain 
viable in the eye for 3 years. It can cause decreased vision, vitritis and papillitis 
Photocoagulation can directly kill the worm  with no post operative 
Inflammation.Xenon arc photocoagulation is very useful. 
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AIM 
To study about effect of lasers in various retinal diseases in a tertiary care centre 
 
OBJECTIVES 
To analyze the visual outcome and disease status whether it has improved or 
maintained or worsened  following frequency doubled Nd yag laser. 
 
METHODOLOGY(MATERIALS AND METHODS) 
Subject selection:- 
150 cases of various retinal diseases attending the retina services at Regional Institute 
of Ophthalmology and Govt. Ophthalmic Hospital were included in the study. 
 
Inclusion criteria 
All age groups 
Patients with Diabetic retinopathy 
                        Vascular occlusions 
                        Vasculitis 
                        Macular edema 
                        High myopia 
                        Central serous chorioretinopathy 
                        Retinopathy of permaturity 
Exclusion criteria:- 
Patients in whom other concurrent traetment like Anti VEGF , vitrectomy is done. 
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Methods:-                   
On first examination,from all patients,detailed present history and past history 
regarding any systemic illness will be recorded.Then they will be subjected to visual 
acuity testing and intraocular pressure testing by goldmann applanation tonometry 
followed anterior segment examination by slit lampbiomicroscopy.This is followed by 
detailed fundus examination with distant direct ophthalmoscopy and slit lamp 
examination with +90 D lens and examination of the peripheries with indirect 
ophthalmoscopy with  +20 D lens. Fundus Fluorescein Angiographic and OCT is done 
for the required patients. 
 
MANAGEMENT: 
         Patients were treated with double frequency Nd YAG laser.PRP, GRID, 
FOCAL, BARRAGE lasers were given as required. 
 
 FOLLOW UP: 
         The immediate followup(within 1 week post laser) and one late followup (after 4 
weeks post laser upto 3 months post laser) will be done for all the patients. At  each 
follow up they will be subjected to visual acuity testing and intraocular pressure 
testing  by goldmann applanation tonometry followed anterior segment examination 
by slit lampbiomicroscopy.This is followed by detailed fundus examination with 
distant direct ophthalmoscopy and slit lamp examination with +90 D lens and 
examination of the peripheries with indirect ophthalmoscopy with +20 D lens.OCT 
will be done. 
55 
 
ANALYSIS PLAN: 
          Patient’s visual acquity pre laser and post laser were analysed.  
          In cases of patients treated with PRP whether the disease has progressed or 
regressed. 
In patients treated with grid  whether the edema has resolved in terms of CFT. 
           In cases of focal laser, improvement is assessed with OCT. 
In cases of retinal breaks, effect of barrage laser  is analysed. 
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RESULTS AND ANALYSIS:AGE DISTRIBUTION: 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                  
 
 
In this study, age group of less than 20 years is 1.8%. between 21 to 40 years is 
8.2%. Between 41 to 60 years is 47.1%. Between 61 to 80 years is 18.8%. More than 
81 years is 1.2%. So the most common age group involved in my study is between 41 
to 60 years. This is the most common age group prone to develop diabetic retinopathy 
and vascular occlusions which forms the major component of the study. 
 
 
Age group 
  Frequency Percent 
  Valid <20 3 1.8 
  21-40 31 18.2 
  41-60 80 47.1 
  61-80 32 18.8 
  >81 2 1.2 
  Total 148 87.1 
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.SEX DISTRIBUTION: 
    
 
 
 
 
 
 
 
 
 
 
 
 
In my study, 114 eyes of males (67%) and 56 eyes of females (33%) were  
Given laser. 
 
 
 
gender 
  Frequency Percent 
Valid Male 
114 67.1 
Female 
56 32.9 
Total 
170 100.0 
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LATERALITY OF EYES: 
 
 
  
 
 
170 eyes of 148 patients were included in the study. There is unilateral involvement in 
 126 eyes and bilateral involvement in 22 eyes. 
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LASERS WHICH WERE DONE IN THE STUDY: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
126 eyes received panretinal photocoagulation, 24 eyes received grid 
Photocoagulation, 9 eyes received focal photocoagulation, barrage laser was given for  
11 myopic eyes. 
 
 
Group 
Valid Frequency Percent 
 PRP 126 74.1 
GRID 24 14.1 
FOCAL 9 5.3 
MYOPIA 11 6.5 
Total 170 100.0 
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DISTRIBUTION OF RETINAL DISEASES RECEIVING PRP: 
 
 
 
       
 
 
 
 
       
         
         
          
2)Early PDR,3)High risk PDR,4)vitreous haemorrhage,5)tractional RD,6)Early PDR 
 with CSME,7)High risk PDR with CSME,8)vascular occlusion,9)vascular occlusion 
 wiy CSME,10)Coats disease,11)Eales disease,12)severe NPDR with CSME,13) 
CSCR,14) Myopia.   
Most common eyes resolving PRP in decreasing order are early PDR ,vascular  
occlusion, high risk PDR,high risk with CSME, vascular occlusion wiyh CSME, early 
PDR with CSME, Eales disease, Cots disease. 
 
undus_pre
a
 
Valid Frequency Percent 
   2.00 63 50.0 
  3.00 18 14.3 
  6.00 3 2.4 
  7.00 6 4.8 
  8.00 27 21.4 
  9.00 4 3.2 
  10.00 2 1.6 
  11.00 3 2.4 
  Total 126 100.0 
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DISTRIBUTION OF RETINAL DISEASES IN PATIENTS RECEIVING GRID: 
 
fundus_pre
a
 
Valid Frequency Percent 
   6.00 3 12.5 
  7.00 4 16.7 
  9.00 4 16.7 
  12.00 13 54.2 
  Total 24 100.0 
     
 
 
2)Early PDR, 3)High risk PDR, 4)vitreous haemorrhage, 5)tractional RD, 
6)Early PDR  with CSME,7)High risk PDR with CSME,8)vascular occlusion, 
9)vascular cclusion  wiy CSME,10)Coats disease,11)Eales disease,12)severe NPDR 
with  CSME,13)CSCR,14)Myopia 
             Most common retinal disease to receive GRID photocoagulation in my study  
is  severe NPDR with CSME . 
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EFFECT OF PRP IN VISUAL ACUITY: 
 
 
 
 
 
 
 
 
 In my study, the mean BCVA before PRP is LogMAR 0.54. but the vision is 
decreasing  after PRP  and it is mean LogMAR 0.68. It is due to increase in macular 
edema, progression of proliferative diabetic retinopathy to vitreous haemorrhage and 
tractional RD. 
 
 
 
 
 
 
PRP 
  Mean 
Std. 
Deviation P value 
 Pair 2 bcva_pre 
0.54 0.28 
0.001 
 bcva_post 
0.68 0.61 
 
63 
 
EFFECT OF GRID ON VISUAL ACUITY: 
 
 
 
 
 
 
 
 
    The mean BCVA before GRID and after GRID is LogMAR 0.70. Post GRID FFA 
is not done in my study in order to find out any leakage to account for the non 
improvement in vision. 
 
 
 
 
 
 
GRID 
  Mean 
Std. 
Deviation P value 
 Pair 2 bcva_pre 0.70 0.18 
0.941 
 bcva_post 0.70 0.22 
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EFFECT OF FOCAL LASER IN BCVA: 
 
 
 
 
 
 
 
 
 
The mean BCVA before FOCAL laser is LogMAR 0.21 and after FOCAL laser 
wasLogMAR 0.11. There is visual improvement in cases of CSCR following FOCAL 
Laser due to resorption of subretinal fluid. 
 
 
 
 
 
 
FOCAL 
  Mean 
Std. 
Deviation P value 
 Pair 2 bcva_pre 0.21 0.20 
0.028 
 bcva_post 0.11 0.14 
 
65 
 
EFFECT OF PRP IN STAGE OF DISEASE: 
 
 
 
 
 
 
 
 
 
 
 
 
2)Early PDR, 3)High risk PDR,4)vitreous haemorrhage,5)tractional RD,6)Early PDR 
with CSME,7)High risk PDR with CSME,8)vascular occlusion,9)vascular occlusion  
wiy CSME,10)Coats disease,11)Eales disease,12)severe NPDR with CSME, 
13)CSCR, 14)Myopia 
fundus_pre * Outcome Crosstabulation
a
 
 Count 
      
  
Outcome 
Total P value 
Improved Maintained Worsen 
fundus_pre 
2.00 23 37 3 63 
<0.0001 
3.00 3 4 11 18 
6.00 0 3 0 3 
7.00 1 5 0 6 
8.00 6 18 3 27 
9.00 1 3 0 4 
10.00 0 2 0 2 
11.00 0 3 0 3 
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In out of 63  early PDR patients, 23 improved,37 maintained,3 worsened from the 
same stage of disease. 
Out of 18 high risk PDR patients 3 improved, 4 maintained, 11 worsened from the 
same stage of disease. 
All 3 patients with early PDR with CSME maintained in the same stage of disease.In 
6 patients with high risk PDR with CSME one improved and remaining 3 remained in 
the same stage of disease. The above 2 sets also received GRID. 
Out of 27 cases of vascular occlusion, 6 improved, 18 maintained and 3 worsened 
from the same stage of disease. This worsening is evident by neovascularisation, and  
vitreous haemorrhage and tractional RD in my study.  
In 4 cases of vascular occlusion with macular edema one improved and 3 maintained  
in the same stage of disease. The above 4 cases also received GRID. 
In 2 cases of coats disease and 3 cases of eales disease, all maintained in the same  
stage of disease. 
In my study when PRP is given in early proliferative stages of diabetic retinopathy  
showed  improvement and reduced worsening than it is given in late stages. In  
vascular occlusion also when it is given as soon as there is minimal  
neovascularisation, there is minimal progression to complications. 
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EFFECT OF GRID IN STAGE OF DISEASE: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2)Early PDR,3)High risk PDR,4)vitreous haemorrhage,5)tractional RD,6)Early PDR  
with CSME,7)High risk PDR with CSME,8)vascular occlusion,9)vascular occlusion  
wiy CSME,10)Coats disease,11)Eales disease,12)severe NPDR with CSME, 
13)CSCR, 14)Myopia 
 
fundus_pre * Outcome Crosstabulation
a
 
 Count 
      
  
Outcome 
Total P value 
Improved Maintained Worsen 
fundus_pre 
6.00 0 2 1 3 
0.020 
7.00 0 4 0 4 
9.00 0 4 0 4 
12.00 7 6 0 13 
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In out of 13 patie ts with severe NPDR with CSME,7 impoved with decrease in 
the  hard exudates and thickening of the retina .In 4 cases each of HR PDR CSME and 
vasc occlusion with macular edema all maintained in the same stage. In 3 cases of 
early PDR ,1 worsened and 3 remained the same. 
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EFFECT OF PRP ON CFT: 
 
 
 
 
 
 
F 
 
 Mean CFT before PRP is 237.37 microns. Mean CFT after PRP was 265.64 
microns. There is a slight increase in CFT  due to increase in macular edema 
following PRP. 
 
 
 
 
 
 
PRP 
  Mean 
Std. 
Deviation P value 
 Pair 1 pre_cft 237.37 27.01 
<0.0001 
 post_cft 265.64 80.26 
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EFFECT OF GRID ON CFT: 
 
 
 
 
 
 
 
 
                      
 
Mean CFT before GRID is 313.79 microns. Mean CFT after GRID was 304.96 
microns.There is a slight decrease in CFT  following GRID due to decrease in 
macular edema. 
 
 
 
      
 
 
Paired Samples Statistics
a
 
 
  Mean 
Std. 
Deviation P value 
 
 
Pair 1 pre_cft 
313.79 15.82 
0.176 
 
 
post_cft 
304.96 28.74 
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EFFECT OF FOCAL LASER ON CFT: 
 
 
Paired Samples Statistics
a
 
 
  Mean 
Std. 
Deviation P value 
 
 
Pair 1 pre_cft 361.00 38.06 
0.009 
 
 
post_cft 306.89 25.61 
  
 
 
 
 Mean CFT before FOCAL is 361 microns. Mean CFT after FOCAL was 306.8  
microns.There is a decrease in CFT  following FOCAL  due to decrease in leakage. 
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DISCUSSION: 
ETDRS study is a study which found out whether deferral or early 
photocoagulation is effective in a case of diabetic retinopathy.According to it,   in 
older patients with early PDR itself it is safer to give scatter  photocoagulation. In  
younger patients it is safer to wait if there is a small NVE   without much   intraretinal 
findings. However if there is NVD and many  intraretinal findings  it is safer to give 
early photocoagulation. In my study photocoagulation in early PDR  is assosciated 
with a significant decrease in progression of disease. 
       
Martin Wand .M.D.,David .K.Dueker.M.D., in their study of PRP  with  ruby 
laser for diabetic retinopathy found that treated eyes had a less tendency to  develop 
neovascularisation of the iris, angle and neovascular glaucoma. Similarly in  my study 
though it is a short term study, there is no significant neovascularisation of  the iris, 
angles and neovascular glaucoma.  
 
Larry. E. Magargal,MD.,Garry.C.Brown., found that prophylactic PRP in high 
risk ischaemic CRVO eyes found to reduce NVG. In our study  Photocoagulation in 
cases with minimal NVE is  assosciated with minimal  progression tocomplications. 
 
According to ETDRS  study grid photocoagulation for macular edema 
Significantly reduced the macular Edema and there is decrease in vision loss  by 
about50%. In my study there is a significant decrease in central foveal thickness  but 
there is no significant change in vision. 
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Olk et al in 1986 to 1991 found that grid photocoagulation for macular edema 
significantly reduced the macular Edema. In my study also there is  significant 
reduction in central foveal thickness. 
 
Watzke et al 1974 with ruby laser did focal laser photocoagulation to the CSCR 
eyes in areas of subretinal leakage.They found that there is a significant  reduction in 
the serous detachment of macula within 5 weeks in the treated group  .However there 
is equal incidence of recurrences later . The subretinal fluid resolved  after 23 weeks 
in the untreated group. In my study also there is resorption of  subretinal fluid in all  
cases with a mean central foveal  thickness reduction of   microns. It is a short term 
study so we are not able to find out the recurrence rate.  
 
Leaver et al ,1979, 1986 and 1988 found that after focal photocoagulation there 
was resorption of subretinal fluid after 6 weeks. In  treated  eyes and it was 16 weeks 
for the untreated eyes. In our study also there is resorption  of fluid on the late follow 
up.  
 
Byer in 1989 in his study found that lattice degeneration  assosciated with or 
without holes in a phakic and normal fellow eyes need not be  treated. Whereas if the 
other eye has retinal detachment it is necessary to do laser in  the eye with lattice 
degeneration with hole.Symptomatic retinal tears should be  treated . In our study we 
had 3 patients who had other eye retinal detachments and  two patients with symptoms 
and two patients with history of RD in the family were treated. The remaining four 
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patients had condensation an  adhesion of vitreous  around the margins of the retinal 
hole were treated. 
    
Folk et al 1989 and 1990 found that prophylactic barrage laserreduced the risk 
for retinal detachment and new breaks. In our study  prophylactic barrage laser was 
given for all patients to prevent further retinal breaks  and detachment. 
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SUMMARY: 
170 eyes of 148 patients were taken for the study. 
The most common age group who were treated with laser in my study is 41 to  
60 years which is the common age group which develop organ specific complications 
following systemic diseases like diabetes and hypertension. 
Sex distribution in our study is 2:1 with propotion to males and females. 
Unilateral involvement is seen in 126 eyes.Bilateral involvement is seen in 22 
 Eyes. 
Lasers which were done in the study are PRP, GRID, FOCAL, BARRAGE.. 
In PRP the most commonly treated eyes are those which are affected by 
diabetic retinopathy in its early proliferative stages followed by vascular occlusion 
There was a mean decrease in BCVA following PRP in the late follow up period. This 
may be due to increase in the macular edema following PRP and worsening of  stages 
according to ETDRS study that is progression to vitreous haemorrhage and retinal 
detachment. In fundus with advancing stage of disease according to ETDRS there is 
less improvement and more worsening following PRP.In vascular occlusion PRP done 
at early stages is assosciated with less complications. 
In  GRID  the most common eyes which got treated are eyes with severe NPDR  
with CSME. There was no significant change in BCVA before and after GRID laser. 
The resolution of macular edema following GRID laser is also dependent on the stage 
of  disease. With early stages there is better resolution of macular edema. Following  
grid there is only less than ten microns decrease in mean central foveal thickness  
which is not so significant. In our study GRID doesn’t have  much better results for 
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macular edema with BCVA and CFT probably longer follow  up will give better 
results. 
In FOCAL laser there is improvement in mean BCVA and resorption of  
subretinal fluid as evident by the mean decrease in central foveal thickness is found.               
In BARRAGE laser for myopia 11 eyes were lasered and there was no  
incidence of RD or new breaks following laser. 
 
LIMITATIONS: 
1)Small sample size 
2)Short term study 
3)No control group to compare the study group 
4)Lack of late follow ups 
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CONCLUSION: 
                In our study ,we found lasers in early stages of any retinal disease found to  
have better outcome  functionally measured in terms of best corrected  visual acuity or 
central foveal thickness and anatomically by assessing the progression  or worsening 
of the disease.  
It is observed that laser in early stages of PDR was found to be assosciated with 
a significant decrease in disease progression  in our study.  
Some of the patients with early PDR treated with laser, though showed no  
improvement , did not worsen. 
           It is observed that GRID laser did not cause any significant change in BCVA  
and central foveal thickness in our study.But pre laser mean BCVA remained the same 
 without any worsening in our study. 
           Most of the patients with vascular occlusion treated with early laser    
maintained well,  without developing complications. 
Some of the vascular occlusion patients with neovascularisation involving  one 
quadrant showed regression of  neovascularisation following laser. 
           It has to be emphasized that laser treatment in early stages of retinal diseases  
has a definite role in arresting the progression of disease thereby improving the  
quality of life of the patient by preventing worse complications arising due to the  
disease per se, atleast to some extent. 
               However due to the attendant complications arising out of laser treatment per  
se  and the area of the retina to be lasered should also be kept in mind and the risk  
benefit ratio to be analysed before choosing the appropriate management.- 
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FRESH PRP MARKn    S 
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NAME AGE SEX RE/LE PRE LASER BCVA PRE LASER BCVA POST LASBCVA IMM FO UPPOST LASBCVA IMM FO UPPO LAS BCVA LATE FOUPPO LAS BCVA LATE FOUPRE LASER FUNDUS PO LAS FUNIMM FO UP PO LAS FUN LAT FOUP PRELASER CFTPOST LASER CFTTYPE OF LASER
1 REVATHY 38 F RE 6/12. 0.3 6/12. 0.3 6/12. 0.3 EARLY PDR EARLY PDR SEVERE NPDR 235 228 PRP
2 REVATHY 38 F LE 6/12. 0.3 6/12. 0.3 6/12. 0.3 EARLY PDR EARLY PDR EARLY PDR 222 274 PRP
3 DEENADAYALAN 54 M LE 6/36. 0.8 6/36. 0.8 6/36. 0.8 EARLY PDR EARLY PDR EARLY PDR 240 290 PRP
4 RANI 60 F RE 6/60. 1 6/60. 1 6/60. 1 HR PDR WITH CSME HR PDR WITH CSME HR PDR WITH CSME 298 335 PRP
5 RANI 60 F LE 6/18. 0.5 6/18. 0.5 6/18. 0.5 EARLY PDR EARLY PDR EARLY PDR 228 263 PRP
6 MOHAN 58 M LE 6/9. 0.2 6/9. 0.2 6/9. 0.2 EARLY PDR EARLY PDR EARLY PDR 229 248 PRP
7 DEVASEKARAN 58 M RE 6/18. 0.5 6/12. 0.3 6/12. 0.3 EARLY PDR EARLY PDR SEVERE NPDR 261 260 PRP
8 JEEVA 38 M RE 6/36. 0.8 6/36. 0.8 6/36. 0.8 EARLY PDR WITH CSME EARLYPDRWITHCSME EARLYPDR WITH CSME 300 PRP
9 JEEVA 38 M LE 6/36. 0.8 6/60. 1 6/60. 1 EARLY PDR WITH CSME EARLR PDR WITH CSME EARLY PDR CSME 295 395 PRP
10 MAHESH 42 M RE 6/12. 0.3 6/9. 0.2 6/9. 0.2 EARLY PDR EARLY PDR SEVERE NPDR 232 262 PRP
11 MOHAMMED 62 M RE 5/60. 1.07 5/60. 1.07 5/60. 1.07 HR PDR HR PDR HR PDR 256 310 PRP
12 MOHAMMED 62 M LE 6/36. 0.8 6/36. 0.8 6/36. 0.8 EARLY PDR EARLY PDR EARLY PDR 239 377 PRP
13 CAUVERY 68 F RE 6/12. 0.3 6/12. 0.3 6/12. 0.3 EARLY PDR EARLY PDR EARLY PDR 248 270 PRP
14 MANI 57 M RE 6/12. 0.3 6/12. 0.3 6/12. 0.3 EARLY PDR EARLY PDR EARLY PDR 225 255 PRP
15 MANI 57 M LE 6/12. 0.3 6/12. 0.3 6/12. 0.3 EARLY PDR EARLY PDR EARLY PDR 237 256 PRP
16 SHANTHI 40 F RE 6/60. 1 6/60. 1 6/60. 1 HR PDR HR PDR HR PDR 265 258 PRP
17 SHANTHI 40 F LE 6/18. 0.5 6/18. 0.5 6/18. 0.5 EARLY PDR EARLY PDR EARLY PDR 240 269 PRP
18 KALIYAPERUMAL 59 M RE 6/18. 0.5 6/18. 0.5 6/18. 0.5 EARLY PDR EARLY PDR EARLY PDR 228 258 PRP
19 SIVASUBRAMANIAN 55 M LE 6/12. 0.3 6/12. 0.3 6/12. 0.3 EARLY PDR EARLY PDR EARLY PDR 245 268 PRP
20 GOVINDHAN 50 M LE 6/18. 0.5 6/18. 0.5 6/12. 0.3 EARLY PDR EARLY PDR SEVERE NPDR 210 239 PRP
21 SEKAR 40 M RE 6/60. 1 6/60. 1 CFCF 1.8 HR PDR HR PDR VIT HAEM 240 NO TARGET PRP
22 KAVITHA 59 F LE 6/24. 0.6 6/24. 0.6 PL 2.8 HR PDR HR PDR TRACTIONAL RD 228 419 PRP
23 VINOTH 27 M RE 6/9. 0.2 6/9. 0.2 6/9. 0.2 EARLY PDR EARLY PDR SEVERE NPDR 224 256 PRP
24 VINOTH 27 M LE 6/9. 0.2 6/9. 0.2 6/9. 0.2 EARLY PDR EARLY PDR SEVERE NPDR 230 265 PRP
25 MUNUSAMY 68 M RE 6/60. 1 6/60. 1 2/60. 1.30 HR PDR HR PDR TRACTIONAL RD 240 375 PRP
26 MUNIYANDI 49 M LE 6/24. 0.6 6/24. 0.6 PL 2.8 HR PDR HR PDR VIT HAEM 245 NO TARGET PRP
27 GOMATHY 55 F RE 6/18. 0.5 6/18. 0.5 6/18. 0.5 EARLY PDR EARLY PDR SEVERE NPDR 218 254 PRP
28 MANIKANDAN 48 M RE 6/36. 0.8 6/36. 0.8 6/36. 0.8 HR PDR HR PDR EARLY PDR 237 266 PRP
29 BADUSHA 30 M RE 6/12. 0.3 6/12. 0.3 6/12. 0.3 EARLY PDR EARLY PDR EARLY PDR 234 256 PRP
30 MUSHAMIN 36 M RE 6/9. 0.2 6/9. 0.2 6/9. 0.2 EARLY PDR EARLY PDR EARLY PDR 210 255 PRP
31  GOBU 63 M RE 6/36. 0.8 6/36. 0.8 6/36. 0.8 EARLY PDR EARLY PDR EARLY PDR 236 251 PRP
32 SATHIYA 55 M RE 6/24. 0.6 6/24. 0.6 6/18. 0.5 EARLY PDR EARLY PDR SEVERE NPDR 241 243 PRP
33 ANGAMMA 70 F RE 5/60. 1.07 5/60. 1.07 PL 2.8 HR PDR HR PDR TRACTIONAL RD 251 PRP
34 SHANTHI 48 F RE 6/18. 0.5 6/18. 0.5 6/18. 0.5 EARLY PDR EARLY PDR SEVERE NPDR 220 250 PRP
35 SHANTHI 48 F LE 6/18. 0.5 6/18. 0.5 6/18. 0.5 EARLY PDR EARLY PDR SEVERE NPDR 225 254 PRP
36 SRINIVASALU 53 M RE 6/18. 0.5 6/18. 0.5 CFCF 1.8 HR PDR HR PDR VIT HAEM 248 NO TARGET PRP
37 MANIVANNAN 38 M LE 6/18. 0.5 6/18. 0.5 6/18. 0.5 HR PDR HR PDR EARLY PDR 210 225 PRP
38 VENKAT 58 M LE 6/18. 0.5 6/18. 0.5 6/18. 0.5 EARLY PDR EARLY PDR EARLY PDR 231 240 PRP
39 SRINIVASAN 52 M RE 6/12. 0.3 6/12. 0.3 6/12. 0.3 EARLY PDR EARLY PDR EARLY PDR 211 217 PRP
40 SEENI 45 M LE 6/60. 1 6/60. 1 HM 2.3 HR PDR HR PDR VIT HAEM 220 NO TARGET PRP
41 VENKARAMAN 72 M LE 6/36. 0.8 6/36. 0.8 1/60. 1.77 HR PDR HR PDR TRACTIONAL RD 258 678 PRP
42 VIJAYA 57 F LE 6/24. 0.6 6/24. 0.6 6/24. 0.6 EARLY PDR EARLY PDR SEVERE NPDR 228 249 PRP
43 ASLAM 45 M LE 6/12. 0.3 6/12. 0.3 6/12. 0.3 EARLY PDR EARLY PDR EARLY PDR 236 250 PRP
44 VATCHALA 54 F RE 6/12. 0.3 6/12. 0.3 6/12. 0.3 EARLY PDR EARLY PDR SEVERE NPDR 218 248 PRP
45 VATCHALA 54 F LE 6/18. 0.5 6/18. 0.5 6/18. 0.5 EARLY PDR EARLY PDR EARLY PDR 214 238 PRP
46 DEVABALAN 58 M RE 6/36. 0.8 6/36. 0.8 6/36. 0.8 EARLY PDR EARLY PDR EARLY PDR 212 256 PRP
47 PACHAIYYAN 62 M RE 6/60. 1 6/60. 1 6/60. 1 HR PDR CSME HR PDR CSME HR PDR CSME 319 339 PRP
48 PACHAIYYAN 62 M LE 6/24. 0.6 6/24. 0.6 6/24. 0.6 EARLY PDR EARLY PDR EARLY PDR 241 252 PRP
49 MOORTHY 72 M RE 6/18. 0.5 6/18. 0.5 6/18. 0.5 EARLY PDR EARLY PDR EARLY PDR 228 251 PRP
50 PERUMAL 65 M LE 6/18. 0.5 6/18. 0.5 6/12. 0.3 EARLY PDR EARLY PDR SEVERE NPDR 212 248 PRP
51 RAMESH 42 M RE 6/36. 0.8 6/36. 0.8 6/36. 0.8 HR PDR CSME HR PDR CSME HR PDR CSME 310 324 PRP
52 RAMESH 42 M LE 6/60. 1 6/60. 1 6/60. 1 HR PDR CSME HR PDR CSME HR PDR CSME 300 325 PRP
53 MOHANA 55 F RE 6/12. 0.3 6/12. 0.3 6/9. 0.2 EARLY PDR EARLY PDR SEVERE NPDR 220 246 PRP
54 RAVI 65 M RE 6/60. 1 6/60. 1 6/60. 1 EARLY PDR EARLY PDR EARLY PDR 214 250 PRP
55 RAVI 65 M LE 5/60. 1.07 5/60. 1.07 5/60. 1.07 HR PDR HR PDR HR PDR 240 256 PRP
56 SUNDARAM 70 M RE 6/18. 0.5 6/18. 0.5 6/18. 0.5 EARLY PDR EARLY PDR EARLY PDR 234 257 PRP
57 MARIAMMAL 56 F RE 6/12. 0.3 6/12. 0.3 6/12. 0.3 EARLY PDR EARLY PDR EARLY PDR 230 226 PRP
58 MARIAMMAL 56 F LE 6/12. 0.3 6/12. 0.3 6/12. 0.3 EARLY PDR EARLY PDR EARLY PDR 227 240 PRP
59 KUMARAN 52 M RE 6/24. 0.6 6/24. 0.6 6/24. 0.6 EARLY PDR EARLY PDR EARLY PDR 234 249 PRP
60 KUMARAN 52 M LE 6/60. 1 6/60. 1 6/60. 1 HR PDR CSME HR PDR CSME EARLY PDR 268 290 PRP
61 GOWRI 60 F RE 6/36. 0.8 6/36. 0.8 6/36. 0.8 EARLY PDR EARLY PDR SEVERE NPDR 204 238 PRP
62 PATTAMMA 60 F RE 6/24. 0.6 6/24. 0.6 6/24. 0.6 EARLY PDR EARLY PDR SEVERE NPDR 210 246 PRP
63 PATTAMMA 60 F LE 6/36. 0.8 6/36. 0.8 6/36. 0.8 EARLY PDR EARLY PDR EARLY PDR 232 260 PRP
64 DHINAKARAN 72 M LE 6/18. 0.5 6/18. 0.5 6/18. 0.5 EARLY PDR EARLY PDR EARLY PDR 222 240 PRP
65 NATARAJAN 68 M RE 6/24. 0.6 6/24. 0.6 6/12. 0.3 EARLY PDR EARLY PDR SEVERE NPDR 250 276 PRP
66 SUGAMALAR 38 F RE 6/36. 0.8 6/36. 0.8 6/60. 1 EARLY PDR WITH CSME EARLY PDR CSME EARLY PDR CSME 298 334 PRP
67 SUGAMALAR 38 F LE 6/60. 1 6/60. 1 5/60. 1.07 HRPDR SCME HR PDR CSME HR PDR CSME 300 280 PRP
68 MOORTHY 58 F RE 6/9. 0.2 6/9. 0.2 6/6. 0 EARLY PDR EARLY PDR SEVERE NPDR 228 246 PRP
69 MARIAMMAL 67 F RE 6/60. 1 6/60. 1 6/60. 1 EARLY PDR EARLY PDR EARLY PDR 217 240 PRP
70 MARIAMMAL 67 F LE 5/60. 1.07 5/60. 1.07 5/60. 1.07 HR PDR HR PDR HR PDR 240 260 PRP
71 SUNDAR 59 M LE 6/18. 0.5 6/18. 0.5 6/18. 0.5 EARLY PDR EARLY PDR EARLY PDR 226 234 PRP
72 ANGAPPAN 60 M LE 6/12. 0.3 6/12. 0.3 6/12. 0.3 EARLY PDR EARLY PDR EARLY PDR 234 240 PRP
73 ANGAPPAN 60 M RE 6/12. 0.3 6/12. 0.3 6/12. 0.3 EARLY PDR EARLY PDR. EARLY PDR 216 259 PRP
74 AHMED 34 M LE 6/12. 0.3 6/12. 0.3 6/12. 0.3 EARLY PDR EARLY PDR EARLY PDR 224 246 PRP
75 FATHIMA 58 F RE 6/24. 0.6 6/24. 0.6 6/24. 0.6 EARLY PDR EARLY PDR EARLY PDR 216 228 PRP
76 GOVINDHAN 66 M LE 6/18. 0.5 6/18. 0.5 6/18. 0.5 EARLY PDR EARLY PDR EARLY PDR 214 236 PRP
77 SAVITHIRI 57 F LE 6/24. 0.6 6/24. 0.6 6/12. 0.3 EARLY PDR EARLY PDR SEVERE NPDR 236 260 PRP
78 ANDAL 72 F LE 5/60. 1.07 5/60. 1.07 PL 2.8 HR PDR HR PDR TRACTIONAL RD 247 PRP
79 SUNDARI 52 F RE 6/24. 0.6 6/24. 0.6 6/24. 0.6 EARLY PDR EARLY PDR SEVERE NPDR 234 246 PRP
80 SUNDARI 52 F LE 6/18. 0.5 6/18. 0.5 6/18. 0.5 EARLY PDR EARLY PDR SEVERE NPDR 236 240 PRP
81 SRINIVASAN 58 M LE 6/36. 0.8 6/36. 0.8 6/36. 0.8 HR PDR HR PDR VIT HAEM 270 NO TARGET PRP
82 MANI 42 M RE 6/36. 0.8 6/36. 0.8 6/36. 0.8 HR PDR HR PDR EARLY PDR 265 289 PRP
83 VIGNESWARAN 56 M LE 6/18. 0.5 6/18. 0.5 6/18. 0.5 EARLY PDR EARLY PDR. EARLY PDR 213 258 PRP
84 SIVAN 59 M RE 6/12. 0.3 6/12. 0.3 6/12. 0.3 EARLY PDR EARLY PDR. HR PDR 214 230 PRP
85 MAHESWARI 59 F LE 6/12. 0.3 6/12. 0.3 6/12. 0.3 EARLY PDR EARLY PDR EARLY PDR 225 236 PRP
86 MAHENDRAN 45 M RE 6/18. 0.5 6/18. 0.5 2/60. 1.47 EARLY PDR EARLY PDR TRACTIONAL RD 240 PRP
87 SIVAPERUMAL 57 M LE 6/36. 0.8 6/36. 0.8 HM 2.3 HR PDR HR PDR VIT HAEM 230 NO TARGET PRP
88 JHANSI 50 F RE 6/12. 0.3 6/12. 0.3 6/12. 0.3 EARLY PDR EARLY PDR EARLY PDR 229 247 PRP
89 MARY 59 F RE 6/18. 0.5 6/18. 0.5 3/60. 1.30 EARLY PDR EARLY PDR HR PDR 220 269 PRP
90 RATHIKA 63 F LE 6/36. 0.8 6/36. 0.8 6/36. 0.8 EARLY PDR EARLY PDR EARLY PDR PRP
91 THOKKAN 21 M RE 6/9. 0.2 6/9. 0.2 6/9. 0.2 EALES DISEASE EALES DISEASE EALES DISEASE 236 240 PRP
92 KARTHIK 27 M RE 6/9. 0.2 6/9. 0.2 6/9. 0.2 EALES DISEASE EALES DISEASE EALES DISEASE 223 253 PRP
93 KARTHIK 27 M LE 6/6. 0 6/6. 0 6/6. 0 EALES DISEASE EALES DISEASE EALES DISEASE 220 247 PRP
94 DHARANI 13 M RE 6/6. 0 6/6. 0 6/6. 0 COATS DISEASE COATS DISEASE COATS DISEASE 223 254 PRP
95 RIYAS 15 M LE 6/6. 0 6/6. 0 6/6. 0 COATS DISEASE COATS DISEASE COATS DISEASE 225 254 PRP
96 KARTHIKEYAN 45 M RE 6/12. 0.3 6/12. 0.3 6/12. 0.3 CRVO CRVO CRVO 228 254 PRP
97 BALAJI 56 M RE 6/9. 0.2 6/9. 0.2 6/9. 0.2 CRVO CRVO CRVO 243 250 PRP
98 RENUKA 69 F LE 6/60. 1 6/60. 1 6/60. 1 ST BRVO  ST BRVO  ST BRVO 178 220 PRP
99 MEGALA 56 F RE 6/12. 0.3 6/12. 0.3 6/12. 0.3  ST BRVO  ST BRVO  ST BRVO 236 234 PRP
100 PURUSHOTTAMAN 72 M LE 6/36. 0.8 6/36. 0.8 4/60. 1.17 CRVO CRVO VIT HAEM 256 310 PRP
101 SHERIF 56 M RE 6/12. 0.3 6/12. 0.3 6/9. 0.2 ST BRVO ST BRVO OLD ST BRVO 210 247 PRP
102 PRAKASH 65 M LE 6/12. 0.3 6/12. 0.3 6/12. 0.3 ST BRVO ST BRVO ST BRVO 224 246 PRP
103 THIRUMAL 60 M RE 6/12. 0.3 6/12. 0.3 6/12. 0.3 IT BRVO IT BRVO IT BRVO 226 235 PRP
104 KANNAN 56 M LE 6/24. 0.6 6/24. 0.6 6/18. 0.5 CRVO WITH ME CRVO WITH ME CRVO EITH ME 327 300 PRP
105 MUTHUKUMAR 48 M RE 6/12. 0.3 6/12. 0.3 6/12. 0.3 IT BRVO IT BRVO IT BRVO 243 267 PRP
106 KALYANI 36 F LE 6/6. 0 6/6. 0 6/6. 0 ST BRVO ST BRVO ST BRVO 236 240 PRP
107 GNANAM 78 F RE 6/24. 0.6 6/24. 0.6 6/24. 0.6 IT BRVO IT BRVO IT BRVO 250 266 PRP
108 MARIAPPAN 65 M LE 6/36. 0.8 6/36. 0.8 PL 2.8 CRVO CRVO VIT HAEM 264 NO TARGET PRP
109 RAMAN 57 M RE 6/12. 0.3 6/12. 0.3 6/12. 0.3 ST BRVO ST BRVO ST BRVO 214 226 PRP
110 PANDIYAN 74 M LE 6/18. 0.5 6/18. 0.5 6/18. 0.5 IT BRVO IT BRVO IT BRVO 226 230 PRP
111 NAINAAR 76 M RE 6/12. 0.3 6/12. 0.3 6/12. 0.3 ST BRVO ST BRVO ST BRVO 236 249 PRP
112 GNANAM 59 F LE 6/12. 0.3 6/12. 0.3 6/12. 0.3 IT BRVO IT BRVO IT BRVO 240 268 PRP
113 GANESAN 63 M LE 6/18. 0.5 6/18. 0.5 6/18. 0.5 ST BRVO ST BRVO ST BRVO 218 227 PRP
114 MARIMUTHU 65 M LE 6/9. 0.2 6/9. 0.2 6/9. 0.2 IT BRVO IT BRVO IT BRVO 230 253 PRP
115 MEGALA 39 F RE 6/12. 0.3 6/12. 0.3 6/12. 0.3 ST BRVO ST BRVO ST BRVO 226 249 PRP
116 CHANDRA 52 F LE 6/24. 0.6 6/24. 0.6 2/60. 1.47 CRVO CRVO TRACTIONAL RD 280 PRP
117 HUDSON 59 M RE 6/12. 0.3 6/12. 0.3 6/12. 0.3 ST BRVO ST BRVO ST BRVO 235 254 PRP
118 JOHN 82 M RE 6/18. 0.5 6/18. 0.5 6/18. 0.5 ST BRVO ST BRVO ST BRVO 236 252 PRP
119 RAJA 56 M RE 6/24. 0.6 6/24. 0.6 6/24. 0.6 IT BRVO IT BRVO IT BRVO 236 243 PRP
120 RAHMAN 67 M RE 6/18. 0.5 6/18. 0.5 6/18. 0.5 ST BRVO ST BRVO ST BRVO 255 280 PRP
121 KANCHANA 55 F LE 6/60. 1 6/60. 1 6/60. 1 ST BRVO WITH ME ST BRVO WITH ME ST BRVO WITH ME 320 298 PRP
122 LILLY 83 F LE 6/18. 0.5 6/18. 0.5 6/18. 0.5 ST BRVO ST BRVO ST BRVO 225 234 PRP
123 SAROJAMMAL 76 F RE 6/12. 0.3 6/12. 0.3 6/12. 0.3 ST BRVO STBRVO ST BRVO 236 223 PRP
124 MAHESH 46 M RE 6/9. 0.2 6/9. 0.2 6/9. 0.2 ST BRVO ST BRVO ST BRVO 215 217 PRP
125 SUBRAMANIAN 50 M RE 6/36. 0.8 6/36. 0.8 6/36. 0.8 CRVO WITH ME CRVO WITH ME CRVO EITH ME 299 270 PRP
126 PRAVEEN 54 M LE 6/24. 0.6 6/24. 0.6 6/24. 0.6 IT BRVO WITH ME IT BRVO WITH ME. IT BRVO WITH ME 318 300 PRP
127 JEEVA 38 M RE 6/36. 0.8 6/36. 0.8 6/36. 0.8 EARLY PDR WITH CSME EARLYPDRWITHCSME EARLYPDR WITH CSME 300 297 GRID
128 JEEVA 38 M LE 6/36. 0.8 6/60. 1 6/60. 1 EARLY PDR WITH CSME EARLR PDR WITH CSME EARLY PDR CSME 295 395 GRID
129 RAMESH 42 M RE 6/36. 0.8 6/36. 0.8 6/36. 0.8 HR PDR CSME HR PDR CSME HR PDR CSME 310 324 GRID
130 RAMESH 42 M LE 6/60. 1 6/60. 1 6/60. 1 HR PDR CSME HR PDR CSME HR PDR CSME 300 325 GRID
131 KUMARAN 52 M LE 6/60. 1 6/60. 1 6/60. 1 HR PDR CSME HR PDR CSME EARLY PDR 298 290 GRID
132 SUGAMALAR 38 F RE 6/36. 0.8 6/36. 0.8 6/60. 1 EARLY PDR WITH CSME EARLY PDR CSME EARLY PDR CSME 298 334 GRID
133 SUGAMALAR 38 F LE 6/60. 1 6/60. 1 5/60. 1.07 HRPDR SCME HR PDR CSME HR PDR CSME 300 280 GRID
134 KANNAN 56 M LE 6/24. 0.6 6/24. 0.6 6/18. 0.5 CRVO WITH ME CRVO WITH ME CRVO EITH ME 327 300 GRID
135 SUBRAMANIAN 50 M RE 6/36. 0.8 6/36. 0.8 6/36. 0.8 CRVO WITH ME CRVO WITH ME CRVO EITH ME 299 270 GRID
136 KANCHANA 55 F LE 6/60. 1 6/60. 1 6/60. 1 ST BRVO WITH ME ST BRVO WITH ME ST BRVO WITH ME 320 298 GRID
137 RAJA 50 M RE 6/24. 0.6 6/24. 0.6 6/18. 0.5 SEVERE NPDR CSME SEVERE NPDR CSME SEVERE NPDR 325 290 GRID
138 RACHAEL 48 F LE 6/18. 0.5 6/18. 0.5 6/18. 0.5 SEVERE NPDR CSME SEVERE NPDR CSME SEVERE NPDR 298 270 GRID
139 MARUTHU 56 M RE 6/24. 0.6 6/24. 0.6 6/24. 0.6 SEVERE NPDR CSME SEVERE NPDR CSME SEVERE NPDR 310 300 GRID
140 PANDU 49 M RE 6/18. 0.5 6/18. 0.5 6/12. 0.3 SEVERE NPDR CSME SEVERE NPDR CSME SEVERE NPDR 328 271 GRID
141 GANNGAMMA 65 F RE 6/24. 0.6 6/24. 0.6 6/24. 0.6 SEVERE NPDR CSME SEVERE NPDR CSME SEV NPDR CSME 337 330 GRID
142 SIVAN 68 M RE 6/24. 0.6 6/24. 0.6 6/24. 0.6 SEVERE NPDR CSME SEVERE NPDR CSME SEV NPDR CSME 341 330 GRID
143 PRISURA 45 F LE 6/24. 0.6 6/24. 0.6 6/18. 0.5 SEVERE NPDR CSME SEVERE NPDR CSME SEVERE NPDR 331 281 GRID
144 VISWANATHAN 43 M RE 6/18. 0.5 6/18. 0.5 6/18. 0.5 IT BRVO WITH ME IT BRVO WITH ME. IT BRV0 WITH ME 320 305 GRID
145 RAVI 54 M RE 6/18. 0.5 6/18. 0.5 6/18. 0.5 SEVERE NPDR CSME SEVERE NPDR CSME SEVERE NPDR 320 297 GRID
146 INIYA 57 F RE 6/36. 0.8 6/36. 0.8 6/36. 0.8 SEVERE NPDR CSME SEVERE NPDR CSME SEV NPDR CSME 346 340 GRID
147 PRATHABAN 74 M RE 6/24. 0.6 6/24. 0.6 6/24. 0.6 SEVERE NPDR CSME SEVERE NPDR CSME SEVERE NPDR 298 270 GRID
148 MUTHHAIH 56 M LE 6/36. 0.8 6/36. 0.8 6/36. 0.8 SEVERE NPDR CSME SEVERE NPDR CSME SEV NPDR CSME 320 314 GRID
149 BALAJI 55 M RE 6/18. 0.5 6/18. 0.5 6/18. 0.5 SEVERE NPDR CSME SEVERE NPDR CSME SEV NPDR CSME 314 308 GRID
150 PRAKASH 59 M LE 6/24. 0.6 6/24. 0.6 6/24. 0.6 SEVERE NPDR CSME SEVERE NPDR CSME  SEV NPDR CSME 296 300 GRID
151 SELVI 35 F RE 6/6. 0 6/6. 0 6/6. 0 CHRONIC CSCR CHRONIC CSCR CHRONIC CSCR 330 280 FOCAL
152 MUSHAMIN 42 M LE 6/12. 0.3 6/9. 0.2 6/9. 0.2 RECURRENT CSCR RECURRENT CSCR RECURRENT CSCR 367 328 FOCAL
153 RAJAVEL 44 M LE 6/9. 0.2 6/6. 0 6/6. 0 CHRONIC CSCR CHRONIC CSCR CHRONIC CSCR 330 300 FOCAL
154 INBA 27 M LE 6/24. 0.6 6/12. 0.3 6/12. 0.3 CHRONIC CSCR CHRONIC CSCR CHRONIC CSCR 450 346 FOCAL
155 MICHAEL 52 M RE 6/6. 0 6/6. 0 6/6. 0 CHRONIC CSCR CHRONIC CSCR CHRONIC CSCR 341 293 FOCAL
156 PANDI 34 M RE 6/12. 0.3 6/9. 0.2 6/9. 0.2 RECURRENT CSCR RECURRENT CSCR RECURRENT CSCR 387 325 FOCAL
157 ROHINI 37 F LE 6/6. 0 6/6. 0 6/6. 0 CHRONIC CSCR CHRONIC CSCR CHRONIC CSCR 345 280 FOCAL
158 RAVI 36 M RE 6/12. 0.3 6/12. 0.3 6/12. 0.3 BILATERAL CSCR BILATERAL CSCR BILATERAL CSCR 357 330 FOCAL
159 RAVI 36 M LE 6/9. 0.2 6/9. 0.2 6/6. 0 BILATERAL CSCR BILATERAL CSCR BILATERAL CSCR 342 280 FOCAL
160 MANIMEGALAI 27 F RE 6/6. 0 6/6. 0 6/6. 0 MYOPIA MYOPIA
161 SIVACHANDRAN 35 M LE 6/6. 0 6/6. 0 6/6. 0 MYOPIA MYOPIA
162 RAVI 19 M LE 6/6. 0 6/6. 0 6/6. 0 MYOPIA MYOPIA
163 MUTHU 22 M RE 6/6. 0 6/6. 0 6/6. 0 MYOPIA MYOPIA
164 GAYATHRI 29 F RE 6/6. 0 6/6. 0 6/6. 0 MYOPIA MYOPIA
165 KARTHIKEYAN 32 M LE 6/6. 0 6/6. 0 6/6. 0 MYOPIA MYOPIA
166BALASUBRAMANIAN 39 M LE 6/6. 0 6/6. 0 6/6. 0 MYOPIA MYOPIA
167 MOOKKAN 26 M LE 6/6. 0 6/6. 0 6/6. 0 MYOPIA MYOPIA
168 RAJAN 23 M RE 6/6. 0 6/6. 0 6/6. 0 MYOPIA MYOPIA
169 BALAJI 41 M RE 6/6. 0 6/6. 0 6/6. 0 MYOPIA MYOPIA
170 PRAVEEN 24 M LE 6/6. 0 6/6. 0 6/6. 0 MYOPIA MYOPIA
TYPE OF LASER
